Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	Mar. 31, 2019	May 07, 2019	Sep. 30, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	Prestige Consumer Healthcare Inc.
Entity Central Index Key	0001295947
Current Fiscal Year End Date	--03-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-K
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		51,798,384
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Public Float			$ 1,953.7

Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Revenues
Total revenues	$ 975,777	$ 1,041,179	$ 882,060
Cost of Sales
Cost of sales excluding depreciation	415,469	459,676	381,333
Cost of sales depreciation	4,732	4,998	441
Cost of sales	420,201	464,674	381,774
Gross profit	555,576	576,505	500,286
Operating Expenses
Advertising and promotion	143,090	147,286	128,359
General and administrative	89,759	85,393	89,113
Depreciation and amortization	27,047	28,428	25,351
(Gain) loss on divestitures	(1,284)	0	51,820
Goodwill and tradename impairment	229,461	99,924	0
Total operating expenses	488,073	361,031	294,643
Operating income	67,503	215,474	205,643
Other (income) expense
Interest income	(217)	(388)	(203)
Interest expense	105,299	106,267	93,546
Loss on extinguishment of debt	0	2,901	1,420
Other expense (income), net	476	(392)	30
Total other expense	105,558	108,388	94,793
(Loss) income before income taxes	(38,055)	107,086	110,850
(Benefit) provision for income taxes	(2,255)	(232,484)	41,455
Net (loss) income	$ (35,800)	$ 339,570	$ 69,395
(Loss) earnings per share:
Basic (in USD per share)	$ (0.69)	$ 6.40	$ 1.31
Diluted (in USD per share)	$ (0.69)	$ 6.34	$ 1.30
Weighted average shares outstanding:
Basic (in shares)	52,068	53,099	52,976
Diluted (in shares)	52,068	53,526	53,362
Comprehensive (loss) income, net of tax:
Currency translation adjustments	$ (6,480)	$ 5,702	$ (2,575)
Unrecognized net gain (loss) on pension plans	48	1,335	(252)
Total other comprehensive (loss) income	(6,432)	7,037	(2,827)
Comprehensive (loss) income	(42,232)	346,607	66,568
Net sales
Revenues
Total revenues	975,692	1,040,792	881,113
Other revenues
Revenues
Total revenues	$ 85	$ 387	$ 947

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2019	Mar. 31, 2018
Current assets
Cash and cash equivalents	$ 27,530	$ 32,548
Accounts receivable, net of allowance of $12,965 and $12,734, respectively	148,787	140,881
Inventories	119,880	118,547
Prepaid expenses and other current assets	4,741	11,501
Total current assets	300,938	303,477
Property, plant and equipment, net	51,176	52,552
Goodwill	578,583	620,098
Intangible assets, net	2,507,210	2,780,916
Other long-term assets	3,129	3,569
Total Assets	3,441,036	3,760,612
Current liabilities
Accounts payable	56,560	61,390
Accrued interest payable	9,756	9,708
Other accrued liabilities	60,663	52,101
Total current liabilities	126,979	123,199
Long-term debt, net	1,798,598	1,992,952
Deferred income tax liabilities	399,575	442,518
Other long-term liabilities	20,053	23,333
Total Liabilities	2,345,205	2,582,002
Commitments and Contingencies – Note 17
Stockholders’ Equity
Preferred stock – $0.01 par value; Authorized – 5,000 shares; Issued and outstanding – None	0	0
Common stock – $0.01 par value; Authorized – 250,000 shares; Issued – 53,670 shares and 53,396 shares at March 31, 2019 and 2018, respectively	536	534
Additional paid-in capital	479,150	468,783
Treasury stock, at cost – 1,871 shares at March 31, 2019 and 353 shares at March 31, 2018	(59,928)	(7,669)
Accumulated other comprehensive loss, net of tax	(25,747)	(19,315)
Retained earnings	701,820	736,277
Total Stockholders’ Equity	1,095,831	1,178,610
Total Liabilities and Stockholders’ Equity	$ 3,441,036	$ 3,760,612

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2019	Mar. 31, 2018
Statement of Financial Position [Abstract]
Allowance for accounts receivable	$ 12,965	$ 12,734
Preferred stock, par value (in USD per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in USD per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	53,670,000	53,396,000
Treasury stock (in shares)	1,871,000	353,000

Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Other Comprehensive (Loss) Income	Retained Earnings
Beginning balance at Mar. 31, 2016	$ 744,336	$ 530	$ 445,182	$ (5,163)	$ (23,525)	$ 327,312
Common stock (in shares) at Mar. 31, 2016		53,066,000
Treasury stock (in shares) at Mar. 31, 2016				306,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	8,148		8,148
Exercise of stock options	$ 4,028	$ 2	4,026
Exercise of stock options (in shares)	126,800	127,000
Issuance of shares related to restricted stock		$ 1	(1)
Issuance of shares related to restricted stock (in shares)		94,000
Treasury share repurchases	$ (1,431)			$ (1,431)
Net (loss) income	69,395					69,395
Treasury share repurchases (in shares)				26,000
Excess tax benefits from share-based awards	900		900
Comprehensive loss	66,568
Common stock (in shares) at Mar. 31, 2017		53,287,000
Treasury stock (in shares) at Mar. 31, 2017				332,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Comprehensive loss	(2,827)				(2,827)
Ending balance at Mar. 31, 2017	822,549	$ 533	458,255	$ (6,594)	(26,352)	396,707
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	8,909		8,909
Exercise of stock options	$ 1,620	$ 0	1,620
Exercise of stock options (in shares)	55,700	56,000
Issuance of shares related to restricted stock		$ 1	(1)
Issuance of shares related to restricted stock (in shares)		53,000
Treasury share repurchases	$ (1,075)			$ (1,075)
Net (loss) income	339,570					339,570
Treasury share repurchases (in shares)				21,000
Comprehensive loss	$ 346,607
Common stock (in shares) at Mar. 31, 2018		53,396,000
Treasury stock (in shares) at Mar. 31, 2018	353,000			353,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Comprehensive loss	$ 7,037				7,037
Ending balance at Mar. 31, 2018	1,178,610	$ 534	468,783	$ (7,669)	(19,315)	736,277
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	7,438		7,438
Exercise of stock options	$ 2,931	$ 0	2,931
Exercise of stock options (in shares)	97,700	98,000
Issuance of shares related to restricted stock		$ 2	(2)
Issuance of shares related to restricted stock (in shares)		176,000
Treasury share repurchases	$ (52,259)			$ (52,259)
Net (loss) income	$ (35,800)
Treasury share repurchases (in shares)	1,449,750			1,518,000
Comprehensive loss	$ (42,232)
Common stock (in shares) at Mar. 31, 2019		53,670,000
Treasury stock (in shares) at Mar. 31, 2019	1,871,000			1,871,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Comprehensive loss	$ (6,432)				(6,432)
Ending balance at Mar. 31, 2019	$ 1,095,831	$ 536	$ 479,150	$ (59,928)	$ (25,747)	$ 701,820

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Operating Activities
Net (loss) income	$ (35,800)	$ 339,570	$ 69,395
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization	31,779	33,426	25,792
(Gain) loss on divestitures	(1,284)	0	51,820
Loss on sale or disposal of property and equipment	216	1,568	573
Deferred income taxes	(40,554)	(269,086)	(5,778)
Amortization of debt origination costs	5,923	6,742	8,633
Excess tax benefits from share-based awards	0	0	900
Stock-based compensation costs	7,438	8,909	8,148
Loss on extinguishment of debt	0	2,901	1,420
Impairment loss	229,461	99,924	0
Lease termination costs	0	214	524
Other non-cash items	421	1,704	581
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	(2,980)	(5,043)	(18,938)
Inventories	(10,535)	(2,482)	(10,262)
Prepaid expenses and other assets	6,887	33,721	(1,996)
Accounts payable	(3,993)	(10,028)	21,447
Accrued liabilities	3,734	(31,495)	2,413
Pension contribution	(1,375)	0	(6,000)
Other	(54)	(435)	0
Net cash provided by operating activities	189,284	210,110	148,672
Investing Activities
Purchases of property, plant and equipment	(10,480)	(12,532)	(2,977)
Proceeds from divestitures	65,912	0	110,717
Proceeds from the sale of property, plant and equipment	0	0	85
Proceeds from working capital arbitration settlement	0	0	1,419
Acquisition of C.B. Fleet, less cash acquired	0	0	(803,839)
Acquisition of C.B. Fleet escrow receipt	0	970	0
Net cash provided by (used in) investing activities	55,432	(11,562)	(694,595)
Financing Activities
Proceeds from issuance of Senior Notes	0	250,000	0
Proceeds from issuance of Term Loan	0	0	1,427,000
Term Loan repayments	(200,000)	(444,000)	(862,500)
Borrowings under revolving credit agreement	45,000	30,000	110,000
Repayments under revolving credit agreement	(45,000)	(45,000)	(105,000)
Payments of debt origination costs	0	(500)	(11,140)
Proceeds from exercise of stock options	2,931	1,620	4,028
Fair value of shares surrendered as payment of tax withholding	(2,281)	(1,075)	(1,431)
Repurchase of common stock	(49,978)	0	0
Net cash (used in) provided by financing activities	(249,328)	(208,955)	560,957
Effects of exchange rate changes on cash and cash equivalents	(406)	1,100	(409)
(Decrease) increase in cash and cash equivalents	(5,018)	(9,307)	14,625
Cash and cash equivalents - beginning of year	32,548	41,855	27,230
Cash and cash equivalents - end of year	27,530	32,548	41,855
Interest paid	98,232	98,572	85,209
Income taxes paid	$ 27,463	$ 24,440	$ 47,999

Business and Basis of Presentation

12 Months Ended

Mar. 31, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Business and Basis of Presentation

Nature of Business

Prestige Consumer Healthcare Inc. (referred to herein as the “Company” or “we”, which reference shall, unless the context requires otherwise, be deemed to refer to Prestige Consumer Healthcare Inc. and all of its direct and indirect 100% owned subsidiaries on a consolidated basis) is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (“OTC”) healthcare and household cleaning products (prior to the sale of our Household Cleaning segment, as discussed in Note 3 to these Consolidated Financial Statements) to mass merchandisers and drug, food, dollar, convenience and club stores and ecommerce channels in North America (the United States and Canada) and in Australia and certain other international markets. Prestige Consumer Healthcare Inc. is a holding company with no operations and is also the parent guarantor of the senior credit facility and the senior notes described in Note 10 to these Consolidated Financial Statements.

Basis of Presentation

Our Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). All significant intercompany transactions and balances have been eliminated in consolidation. Our fiscal year ends on March 31st of each year. References in these Consolidated Financial Statements or notes to a year (e.g., “2019”) mean our fiscal year ended on March 31st of that year.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ from those estimates. As discussed below, our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances, inventory obsolescence, and accounting for income taxes and related uncertain tax positions.

Cash and Cash Equivalents

We consider all short-term deposits and investments with original maturities of three months or less to be cash equivalents. At March 31, 2019, approximately 37% of our cash is held by a bank in Sydney, Australia. Substantially all of our remaining cash is held by a large regional bank with headquarters in California. We do not believe that, as a result of this concentration, we are subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships. The Federal Deposit Insurance Corporation (“FDIC”) and Securities Investor Protection Corporation (“SIPC”) insures our domestic balances, up to $250,000 and $500,000, with a $250,000 limit for cash, respectively. Substantially all of the Company's cash balances at March 31, 2019 are uninsured. We had non-cash financing activities in 2018 of $0.6 million relating to the March 2018 debt refinancing (see Note 10 for further details).

Accounts Receivable

We extend non-interest-bearing trade credit to our customers in the ordinary course of business. We maintain an allowance for doubtful accounts receivable based upon historical collection experience and expected collectability of the accounts receivable. In an effort to reduce credit risk, we (i) have established credit limits for all of our customer relationships, (ii) perform ongoing credit evaluations of customers’ financial condition, (iii) monitor the payment history and aging of customers’ receivables, and (iv) monitor open orders against an individual customer’s outstanding receivable balance.

Inventories

Inventories are stated at the lower of cost or net realizable value, where cost is determined by using the first-in, first-out method. We reduce inventories for the diminution of value resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its estimated net realizable value. Factors utilized in the determination of estimated net realizable value include (i) product expiration dates, (ii) current sales data and historical return rates, (iii) estimates of future demand, (iv) competitive pricing pressures, (v) new product introductions, and (vi) component and packaging obsolescence.

Property, Plant and Equipment

Property, plant and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:



	Years
Building	15 - 40
Machinery	3 - 15
Computer equipment and software	3 - 5
Furniture and fixtures	7 - 10
Leasehold improvements	*

*Leasehold improvements are amortized over the lesser of the lease term or the estimated useful life of the related assets.

Expenditures for maintenance and repairs are charged to expense as incurred. When an asset is sold or otherwise disposed of, we remove the cost and associated accumulated depreciation from the respective accounts and recognize the resulting gain or loss in the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss).

Property, plant and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.

Goodwill

The excess of the purchase price over the fair market value of assets acquired and liabilities assumed in business combinations is classified as goodwill. Goodwill is not amortized, although the carrying value is tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired. Goodwill is tested for impairment at the reporting unit level, which is one level below the operating segment level. An impairment loss is recognized if the carrying amount of the reporting unit exceeds its fair value.

Intangible Assets

Intangible assets, which are comprised primarily of tradenames, are stated at cost less accumulated amortization. For intangible assets with finite lives, amortization is computed using the straight-line method over estimated useful lives, typically ranging from 10 to 30 years.

Indefinite-lived intangible assets are tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired. Intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amount may exceed their fair values and may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.

Debt Origination Costs

We have incurred debt origination costs in connection with the issuance of long-term debt. These costs are amortized over the term of the related debt, using the effective interest method for our bonds and our term loan facility and the straight-line method for our revolving credit facility. Costs associated with our revolving credit facility are reported as a long-term asset and costs related to our senior notes and the term loan facility are recorded as a reduction of debt.

Revenue Recognition

Nature of Goods and Services

We recognize revenue from product sales. We primarily ship finished goods to our customers and operate in two segments: North American OTC Healthcare and International OTC Healthcare. We sold our Household Cleaning segment on July 2, 2018 (see Note 3 for further details). The segments are based on differences in the nature of products and geographical area. The North America and International OTC Healthcare segments market a variety of personal care and over-the-counter products in the following product groups: Analgesics, Cough & Cold, Women's Health, Gastrointestinal, Eye & Ear Care, Dermatologicals, and Oral Care. Prior to its sale, the Household Cleaning segment focused on the sale of cleaning products. Our products are distinct and separately identifiable on customer contracts or invoices, with each product sale representing a separate performance obligation.

We sell consumer products under a variety of brands through a broad distribution platform that includes mass merchandisers and drug, food, dollar, convenience and club stores and e-commerce channels, all of which sell our products to consumers.

See Note 19 for disaggregated revenue information.

Satisfaction of Performance Obligations

Revenue is recognized when control of a promised good is transferred to a customer, in an amount that reflects the consideration that we expect to be entitled to receive in exchange for that good. This occurs either when finished goods are transferred to a common carrier for delivery to the customer or when product is picked up by the customer or the customer’s carrier. This represents a change in the timing of revenue recognition for some sales. Refer to the table in "Recently Adopted Accounting Pronouncements" below for disclosure of the adoption date impacts.

Once a product has transferred to the common carrier or been picked up by the customer, the customer is able to direct the use of, and obtain substantially all of the remaining benefits from, the product. It is at this point that we have a right to payment and the customer has legal title.

Variable Consideration

Provisions for certain rebates, customer promotional programs, product returns, and discounts to customers are accounted for as variable consideration and recorded as a reduction in sales.

We record an estimate of future product returns, chargebacks and logistic deductions concurrent with recording sales, which is made using the most likely amount method which incorporates (i) historical return rates, (ii) current economic trends, (iii) changes in customer demand, (iv) product acceptance, (v) seasonality of our product offerings, and (vi) the impact of changes in product formulation, packaging and advertising.

We participate in the promotional programs of our customers to enhance the sale of our products. These promotional programs consist of direct-to-consumer incentives, such as coupons and temporary price reductions, as well as incentives to our customers, such as allowances for new distribution, including slotting fees, and cooperative advertising. The costs of such activities are recorded as a reduction to revenue when the related sale takes place. Estimates of the costs of these promotional programs are derived using the most likely amount method, which incorporates (i) historical sales experience, (ii) the current promotional offering, (iii) forecasted data, (iv) current market conditions, and (v) communication with customer purchasing/marketing personnel. At the completion of the promotional program, the estimated amounts are adjusted to actual results.

Practical Expedients

Due to the nature (short duration) of our contracts with customers, we apply the practical expedient related to the disclosure of remaining performance obligations. Remaining performance obligations relate to contracts with a duration of less than one year, in which we have the right to invoice the customer at the time the performance obligation is satisfied for the amount of revenue recognized at that time. Accordingly, we have elected the practical expedient available under Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 606 not to disclose remaining performance obligations for our contracts. The period between when control of the promised products transfers to the customer and when the customer pays for the products is one year or less. As such, we do not adjust product consideration for the effects of a significant financing component. The amortization period of any asset resulting from incremental costs of obtaining a contract would be one year or less.

We expense incremental direct costs of obtaining a contract (broker commissions) when the related sale takes place.

We account for shipping and handling costs as fulfillment activities and therefore recognize them upon shipment of goods.

The impact of adopting ASC 606 on our Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) is as follows:



	Year Ended March 31, 2019
(In thousands)	As Reported			Impact of Change			Without Adoption of ASC 606
Total revenues	$	975,777		$	(14,756	)	$	961,021
Cost of sales	$	420,201		$	(5,220	)	$	414,981
Total operating expenses	$	488,073		$	(319	)	$	487,754
Loss before income taxes	$	(38,055	)	$	(9,217	)	$	(47,272	)
(Benefit) for income taxes	$	(2,255	)	$	(2,662	)	$	(4,917	)
Net loss	$	(35,800	)	$	(6,555	)	$	(42,355	)

Cost of Sales

Cost of sales includes costs related to the manufacturing of our products, including raw materials, direct labor and indirect plant costs (including but not limited to depreciation), warehousing costs, inbound and outbound shipping costs, and handling and storage costs. Warehousing, shipping and handling and storage costs were $56.4 million for 2019, $64.7 million for 2018 and $46.2 million for 2017.

Advertising and Promotion Costs

Advertising and promotion costs are expensed as incurred. Allowances for distribution costs associated with products, including slotting fees, are recognized as a reduction of sales.

Stock-based Compensation

We recognize stock-based compensation expense by measuring the cost of services to be rendered based on the grant-date fair value of the equity award. Compensation expense is recognized over the period a grantee is required to provide service in exchange for the award, generally referred to as the requisite service period.

Pension Expense

Certain employees of C.B. Fleet Company, Inc. ("Fleet") are covered by defined benefit pension plans. The Company’s policy is to contribute at least the minimum amount required under The Employee Retirement Income Security Act of 1974 ("ERISA"). The Company may elect to make additional contributions. Benefits are based on years of service and levels of compensation. On December 16, 2014, the decision was made to freeze the benefits under the Company's U.S. qualified defined benefit pension plan with an effective date of March 1, 2015.

The funded status of our pension plans is dependent upon many factors, including returns on invested assets and the level of certain market interest rates. We review pension assumptions regularly and we may from time to time make voluntary contributions to our pension plans that exceed the amounts required by statute. Changes in interest rates and the market value of the securities held by the plans could materially change the funded status of the plans, positively or negatively, and affect the level of pension expense and required contributions in fiscal 2020 and beyond.

Income Taxes

On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act ("Tax Act"). The Tax Act represented significant U.S. federal tax reform legislation that includes a permanent reduction to the U.S. federal corporate income tax rate. The permanent reduction to the federal corporate income tax rate resulted in a one-time benefit of $267.0 million related to the value of our deferred tax liabilities and a benefit of $3.2 million related to the lower blended tax rate on our earnings in the year ended March 31, 2018, resulting in a net benefit of $270.2 million. Additionally, the Tax Act subjects certain of our cumulative foreign earnings and profits to U.S. income taxes through a deemed repatriation, which resulted in a charge of $1.9 million during the year ended March 31, 2018.

Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.

The Income Taxes topic of the FASB ASC 740 prescribes a recognition threshold and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The guidance only allows the recognition of those tax benefits that have a greater than 50% likelihood of being sustained upon examination by the various taxing authorities. As a result, we have applied such guidance in determining our tax uncertainties.

We are subject to taxation in the United States and various state and foreign jurisdictions.

We classify penalties and interest related to unrecognized tax benefits as income tax expense in the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss).

(Loss) Earnings Per Share

Basic earnings (loss) per share is computed based on income available to common stockholders and the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed based on income available to common stockholders and the weighted-average number of shares of common stock outstanding plus the effect of potentially dilutive common shares outstanding during the period using the treasury stock method, which includes stock options and restricted stock units ("RSUs"). Potential common shares, composed of the incremental common shares issuable upon the exercise of outstanding stock options and unvested RSUs, are included in the diluted earnings per share calculation to the extent that they are dilutive. In loss periods, the assumed exercise of in-the-money stock options and RSUs has an antidilutive effect, and therefore these instruments are excluded from the computation of diluted earnings per share. The following table sets forth the computation of basic and diluted earnings per share:



	Year Ended March 31,
(In thousands, except per share data)	2019			2018		2017
Numerator
Net (loss) income	$	(35,800	)	$	339,570	$	69,395

Denominator
Denominator for basic (loss) earnings per share - weighted average shares outstanding	52,068			53,099		52,976
Dilutive effect of unvested restricted stock units and options issued to employees and directors	—			427		386
Denominator for diluted (loss) earnings per share	52,068			53,526		53,362

(Loss) earnings per Common Share:
Basic net (loss) earnings per share	$	(0.69	)	$	6.40	$	1.31

Diluted net (loss) earnings per share	$	(0.69	)	$	6.34	$	1.30

For 2019, 2018, and 2017 there were 1.4 million, 0.4 million, and 0.2 million shares, respectively, attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive.

Recently Adopted Accounting Pronouncements

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers - Topic 606, including new FASB Accounting ASC 606, which supersedes the revenue recognition requirements in FASB ASC 605. Along with amendments issued in 2015 and 2016, the new guidance eliminated industry-specific revenue recognition guidance under previous GAAP and replaced it with a principle-based approach for determining revenue. The core principle of the new guidance is that an entity should recognize revenue for the transfer of goods and services equal to an amount it expects to be entitled to receive for those goods and services. The new standard also requires additional disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. The new guidance permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively by recognizing the cumulative effect of initially applying the guidance to all contracts existing at the date of initial application (the modified retrospective method). The ASU, as amended, is effective for annual reporting periods beginning after December 15, 2017. We adopted this guidance effective April 1, 2018 using the modified retrospective transition method and applied it to contracts that were not completed at the adoption date.

The effects of this recently adopted accounting pronouncement to our Consolidated Balance Sheet as of April 1, 2018 are as follows:



(In thousands)	Balance March 31, 2018		New Revenue Standard Adjustment			April 1, 2018
Accounts receivable, net	$	140,881	$	5,438		$	146,319
Inventories	118,547		(1,768		)	116,779
Other accrued liabilities	52,101		1,926			54,027
Deferred income tax liabilities	442,518		401			442,919
Retained earnings	736,277		1,343			737,620

In March 2017, the FASB issued ASU 2017-07, Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost, which changes the presentation of net periodic benefit cost related to employer sponsored defined benefit plans and other postretirement benefits. Under this ASU, service cost should be included in the same income statement line item as other compensation costs arising from services rendered during the period, while other components of net periodic benefit pension cost should be presented separately outside of operating income. Additionally, only service costs may be capitalized in assets. Entities should apply the guidance on the presentation of the components of net periodic benefit cost in the income statement retrospectively. The guidance limiting the capitalization of net periodic benefit cost in assets to the service cost component should be applied prospectively. The standard is effective for annual reporting periods beginning after December 15, 2017. The adoption of this standard in the first quarter of 2019 required us to reclassify certain pension costs out of operating income and did not have a material impact on our Consolidated Financial Statements.

In March 2018, the FASB issued ASU 2018-05, Income Taxes (Topic 740). The amendments in this update reflect the income tax accounting implications of the Tax Act. See Note 15 for a discussion of the Tax Act, which was signed into law on December 22, 2017, and the impact it has had, and may have, on our business and financial results.

In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The amendments in this update allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Act. See Note 15 for a discussion of the Tax Act and the impact it has had, and may have, on our business and financial results. The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. We have early adopted ASU 2018-02, and the adoption did not have a material impact on our Consolidated Financial Statements.

In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. The amendments in this update clarify the definition of a business to help companies evaluate whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The amendments in this update are effective for public companies for annual periods beginning after December 15, 2017, including interim periods within those periods. We adopted this standard effective April 1, 2018, and the adoption did not have a material impact on our Consolidated Financial Statements.

In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments. The amendments in this update provide clarification and guidance on eight cash flow classification issues. For public companies, the amendments in this update are effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. We adopted this standard effective April 1, 2018, and the adoption did not have a material impact on our Consolidated Financial Statements.

In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350). The amendments in this update simplify the test for goodwill impairment by eliminating Step 2 from the impairment test, which required the entity to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities following the procedure that would be required in determining fair value of assets acquired and liabilities assumed in a business combination. The amendments in this update are effective for public companies for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. We early adopted this standard effective February 28, 2019.

Recently Issued Accounting Pronouncements

In August 2018, the FASB issued ASU 2018-14, Compensation - Retirement Benefits - Defined Benefit Plans - General (Topic 715-20): Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans. The amendments in this update modify the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans by eliminating certain required disclosures and incorporating others. The amendments are effective for public companies for fiscal years ending after December 15, 2020. We do not expect the adoption of this standard to have a material impact on our Consolidated Financial Statements.

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this update modify the disclosure requirements in Topic 820, with a particular focus on Level 3 investments, by eliminating certain required disclosures and incorporating others. The amendments are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. We do not expect the adoption of this standard to have a material impact on our Consolidated Financial Statements.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments. The amendments in this update provide financial statement users with more useful information about expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. In November 2018, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments - Credit Losses, to clarify that receivables arising from operating leases are not within the scope of the credit loss standard, but should be accounted for in accordance with the lease standard. The amendments to this update are effective for us for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. We are currently evaluating the impact of adopting this guidance on our Consolidated Financial Statements.

In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842),” which requires lessees to recognize a right-of-use asset and lease liability on the balance sheet. Recognition, measurement and presentation of expenses will depend on classification as finance or operating lease. ASU 2016-02 was effective for us on April 1, 2019 and, pursuant to the standard, we adopted the new standard effective April 1, 2019 using the modified retrospective method and will not restate comparative periods. We are electing the package of practical expedients permitted under the transition guidance, as well as choosing to combine lease and non-lease components and to keep leases with an initial term of 12 months or less off the balance sheet and recognize the associated lease payments in the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) on a straight-line basis over the lease term. We are in the process of determining the impact of the adoption of ASU 2016-02 on our Consolidated Financial Statements, but this standard will have a material impact on our Consolidated Balance Sheets. See Note 17 for a summary of our undiscounted minimum rental commitments under operating leases as of March 31, 2019.

Acquisition	12 Months Ended
Acquisition	Mar. 31, 2019
Business Combinations [Abstract]
Acquisitions	Acquisition The following acquisition was accounted for in accordance with Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition. Acquisition of Fleet On January 26, 2017, the Company completed the acquisition of Fleet pursuant to an Agreement and Plan of Merger, dated as of December 22, 2016, for $823.7 million plus cash on hand at closing and subject to certain adjustments related to net working capital. The purchase price was funded by available cash on hand, additional borrowings under our asset-based revolving credit facility, and a new $740.0 million senior secured incremental term loan under the 2012 Term Loan. As a result of the merger, we acquired women's health, gastrointestinal and dermatological care OTC brands, including Summer’s Eve, Fleet, and Boudreaux's Butt Paste, as well as a “mix and fill” manufacturing facility in Lynchburg, Virginia. The financial results from the Fleet acquisition are included in the Company's North American and International OTC Healthcare segments.

Divestitures and Sale of License Rights

12 Months Ended

Mar. 31, 2019

Discontinued Operations and Disposal Groups [Abstract]

Divestitures and Sale of License Rights

Divestitures

On July 2, 2018, we sold the Comet®, Spic and Span®, Chore Boy®, Chlorinol® and Cinch® brands, as well as associated inventory. These brands represented our Household Cleaning segment.

As a result of this transaction, we received proceeds of approximately $65.9 million and recorded a pre-tax gain on sale of $1.3 million. The net proceeds were used to repay debt.

The following table sets forth the components of the assets sold and the pre-tax gain recognized on the sale in July 2018:



(In thousands)	July 2, 2018
Components of assets sold:
Inventory	$	6,644
Property, plant and equipment, net	653
Goodwill	6,245
Intangible assets, net	49,315
Assets sold	62,857
Total purchase price received	65,912
	(3,055		)
Costs to sell	1,771
Pre-tax gain on divestiture	$	(1,284	)

On July 7, 2016, we completed the sale of the Pediacare®, New Skin® and Fiber Choice® brands for $40.0 million plus the cost of inventory. During the year ended March 31, 2017, we recorded a pre-tax loss on sale of $56.2 million. The proceeds were used to repay debt and related income taxes due on the dispositions.

Concurrent with the completion of the sale of these brands, we entered into an option agreement with the buyer to purchase Dermoplast® at a specified earnings multiple as defined in the option agreement. The buyer paid a $1.25 million deposit for this option in September 2016 and later notified us of its election to exercise the option. In December 2016, we completed the sale of the Dermoplast® brand, and in a separate transaction, the e.p.t® brand, for an aggregate amount of $59.6 million. As a result, we recorded a pre-tax net gain on these divestitures of $3.9 million.

Sale of license rights

Historically, we received royalty income from the licensing of the names of certain of our brands in geographic areas or markets in which we do not directly compete. We had royalty agreements for the Comet® brand for several years, which included options on behalf of the licensee to purchase license rights in certain geographic areas and markets in perpetuity. In December 2014, we amended those agreements, and we sold rights to use of the Comet® brand in certain Eastern European countries to a third party licensee in exchange for $10.0 million as a partial early buyout of the license. The amended agreement provided that we would continue to receive royalty payments of $1.0 million per quarter for the remaining geographic areas and also granted the licensee an option to acquire the license rights in the remaining geographic areas any time after June 30, 2016. In July 2016, the licensee elected to exercise its option. In August 2016, we received $11.0 million for the purchase of the remaining license rights and, as a result, we recorded a pre-tax gain of $1.2 million and reduced our indefinite-lived tradenames by $9.0 million. Furthermore, the licensee was no longer required to make additional royalty payments to us, and as a result, our royalty income was reduced accordingly. We sold the Comet® brand on July 2, 2018.

Accounts Receivable

12 Months Ended

Mar. 31, 2019

Receivables [Abstract]

Accounts Receivable

Accounts receivable consist of the following:



	March 31,
(In thousands)	2019			2018
Components of Accounts Receivable
Trade accounts receivable	$	161,047		$	152,832
Other receivables	705			783
	161,752			153,615
Less allowances for discounts, returns and uncollectible accounts	(12,965		)	(12,734		)
Accounts receivable, net	$	148,787		$	140,881

- Definition

The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.

+ References + Details

Goodwill

12 Months Ended

Mar. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill

The following table summarizes the changes in the carrying value of goodwill by operating segment for each of 2017, 2018, and 2019:



(In thousands)	North American OTC Healthcare			International OTC Healthcare			Household Cleaning			Consolidated
Balance – March 31, 2017
Goodwill	$	706,623		$	32,554		$	71,405		$	810,582
Accumulated impairment losses	(130,170		)	—			(65,160		)	(195,330		)
Balance - March 31, 2017	576,453			32,554			6,245			615,252

2018 Adjustments ^(a)	4,481			—			—			4,481
Effects of foreign currency exchange rates	—			365			—			365

Balance – March 31, 2018
Goodwill	711,104			32,919			71,405			815,428
Accumulated impairment losses	(130,170		)	—			(65,160		)	(195,330		)
Balance - March 31, 2018	580,934			32,919			6,245			620,098

2019 Additions	—			—			—			—
2019 Reductions:	—			—			—			—
Goodwill ^(b)	—			—			(71,405		)	(71,405		)
Accumulated impairment loss ^(b)	—			—			65,160			65,160
Effects of foreign currency exchange rates	—			(1,729		)	—			(1,729		)
Impairment loss	(33,541		)	—			—			(33,541		)

Balance – March 31, 2019
Goodwill	711,104			31,190			—			742,294
Accumulated impairment losses	(163,711		)	—			—			(163,711		)
Balance - March 31, 2019	$	547,393		$	31,190		$	—		$	578,583

(a) Amount relates to a measurement period adjustment recorded during 2018, associated with our Fleet acquisition.

(b) As discussed in Note 3, on July 2, 2018, we sold our Household Cleaning segment. As a result, we decreased goodwill by $6.2 million, net of accumulated impairment charges.

At February 28, 2019, in conjunction with our annual test for goodwill impairment, which coincides with our annual strategic planning process, we recorded an impairment charge of $33.5 million relating to our North American Oral Care reporting unit. The goodwill impairment was primarily a result of the DenTek and Efferdent/Effergrip tradename impairments discussed in Note 8.

At February 28, 2018, in conjunction with the annual test for goodwill impairment, there were no indicators of impairment under the analysis and accordingly, no impairment charge was taken.

We identify our reporting units in accordance with the FASB ASC Subtopic 280. The carrying value and fair value for intangible assets and goodwill for a reporting unit are calculated based on key assumptions and valuation methodologies previously discussed. The discounted cash flow methodology is a widely-accepted valuation technique utilized by market participants in the transaction evaluation process and has been applied consistently. We also considered our market capitalization at February 28, 2019 and 2018, as compared to the aggregate fair values of our reporting units, to assess the reasonableness of our estimates pursuant to the discounted cash flow methodology. The estimates and assumptions made in assessing the fair value of our reporting units and the valuation of the underlying assets and liabilities are inherently subject to significant uncertainties. Consequently, changing rates of interest and inflation, declining sales or margins, increases in competition, changing consumer preferences, technical advances, or reductions in advertising and promotion may require an impairment charge to be recorded in the future.

As a result of our analysis at February 28, 2019, all other reporting units tested had a fair value that exceeded their carrying value by at least 10%, with the exception of the North American Women's Health reporting unit. We performed a sensitivity analysis on our weighted average cost of capital and we determined that a 50 basis point increase in the weighted average cost of capital would not have resulted in any of our other reporting unit’s fair value being less than their carrying value. Additionally, a 50 basis point decrease in the terminal growth rate used for each reporting unit would also not have resulted in any of our other reporting unit's fair value being less than their carrying value.

Intangible Assets

12 Months Ended

Mar. 31, 2019

Intangible Assets, Net (Excluding Goodwill) [Abstract]

Intangible Assets

A reconciliation of the activity affecting intangible assets, net for each of 2019 and 2018 is as follows:



	Year Ended March 31, 2019
(In thousands)	Indefinite- Lived Tradenames			Finite-Lived Tradenames and Customer Relationships			Totals
Gross Carrying Amounts
Balance – March 31, 2018	$	2,490,303		$	441,314		$	2,931,617
Reclassifications	(25,152		)	25,152			—
Reductions	(30,562		)	(34,889		)	(65,451		)
Tradename impairment	(154,967		)	(40,953		)	(195,920		)
Effects of foreign currency exchange rates	(6,431		)	(341		)	(6,772		)
Balance – March 31, 2019	$	2,273,191		$	390,283		$	2,663,474

Accumulated Amortization
Balance – March 31, 2018	$	—		$	150,701		$	150,701
Additions	—			21,767			21,767
Reductions	—			(16,136		)	(16,136		)
Effects of foreign currency exchange rates	—			(68		)	(68		)
Balance – March 31, 2019	$	—		$	156,264		$	156,264

Intangible assets, net – March 31, 2019	$	2,273,191		$	234,019		$	2,507,210

Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	2,195,617		$	228,743		$	2,424,360
International OTC Healthcare	77,574			5,276			82,850
Intangible assets, net – March 31, 2019	$	2,273,191		$	234,019		$	2,507,210



	Year Ended March 31, 2018
(In thousands)	Indefinite- Lived Tradenames			Finite-Lived Tradenames and Customer Relationships			Totals
Gross Carrying Amounts
Balance – March 31, 2017	$	2,589,155		$	441,801		$	3,030,956
Tradename impairment	(99,300		)	(624		)	(99,924		)
Effects of foreign currency exchange rates	448			137			585
Balance – March 31, 2018	$	2,490,303		$	441,314		$	2,931,617

Accumulated Amortization
Balance – March 31, 2017	$	—		$	127,343		$	127,343
Additions	—			23,349			23,349
Effects of foreign currency exchange rates	—			9			9
Balance – March 31, 2018	$	—		$	150,701		$	150,701

Intangible assets, net – March 31, 2018	$	2,490,303		$	290,613		$	2,780,916

Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	2,375,736		$	265,356		$	2,641,092
International OTC Healthcare	84,006			6,068			90,074
Household Cleaning	30,561			19,189			49,750
Intangible assets, net – March 31, 2018	$	2,490,303		$	290,613		$	2,780,916

As discussed in Note 3, on July 2, 2018, we sold our Household Cleaning segment. As a result, we decreased our indefinite-lived intangibles by $30.5 million and our net finite-lived trademarks by $18.8 million.

During the fourth quarter of each fiscal year in conjunction with our strategic planning process, we perform our annual impairment analysis. We utilized the excess earnings method to estimate the fair value of our individual indefinite-lived intangible assets. The discount rate utilized in the analyses, as well as future cash flows, may be influenced by such factors as changes in interest rates and rates of inflation. Additionally, should the related fair values of intangible assets be adversely affected as a result of declining sales or margins caused by competition, changing consumer preferences, technological advances or changes in advertising and promotional expenses, we may be required to record impairment charges in the future.

As a result of our analysis at February 28, 2019, the fair values of three of our indefinite-lived intangible assets, Fleet, DenTek and Efferdent/Effergrip, did not exceed the carrying values and as such, impairment charges of $155.0 million were recorded. In addition, in connection with the impairment analysis, the Efferdent/Effergrip intangible asset was determined to have a finite life, and as such it will be amortized prospectively over its estimated remaining useful life of 15 years as we believe this life best reflects the period over which we believe this brand will contribute to our cash flows. The impairment charges were the result of our reassessment of the long-term sales projections for these brands during our annual planning cycle as well as an overall increase in the discount rate used to value the brands.

As a result of our analysis at February 28, 2019, all other indefinite-lived intangible assets tested had a fair value that exceeded their carrying value by at least 10%, with the exception of one of the significant tradenames within our North American Women's Health reporting unit. We performed a sensitivity analysis of our weighted average cost of capital and we determined that a 50 basis point increase in the weighted average cost of capital used to value the indefinite-lived intangibles would have resulted in an additional impairment of $17.4 million. Additionally, a 50 basis point decrease in the terminal growth rate used for each of our indefinite-lived intangibles would have resulted in an additional impairment of $8.9 million.

Also as a result of our analysis at February 28, 2019, the fair value of several of our non-core finite-lived trademarks did not exceed their carrying values, and as such, impairment charges of $41.0 million were recorded. The impairment charges were the result of our reassessment of the long-term sales projections for the associated brands during our annual planning cycle, in certain instances the discontinuance of brands, as well as an overall increase in the discount rate used to value the brands.

The assets impaired in 2019 are all part of our North America OTC segment.

As a result of our analysis at February 28, 2018, the fair values of two of our indefinite-lived intangible assets, Beano and Comet®, did not exceed the carrying values and as such, impairment charges of $28.6 million and $70.7 million, respectively, were recorded in 2018 relating to these two tradenames. We also recorded an impairment charge on one of our finite-lived trademarks in 2018 of $0.6 million. Beano and the finite-lived intangible are part of our North American OTC Healthcare segment and Comet ® was part of our Household Cleaning segment (prior to the sale of our Household Cleaning segment as discussed in Note 3).

The weighted average remaining life for finite-lived intangible assets at March 31, 2019 was approximately 11.9 years, and the amortization expense for the year ended March 31, 2019 was $21.8 million. At March 31, 2019, finite-lived intangible assets are expected to be amortized over their estimated useful life, which ranges from a period of 10 to 30 years, and the estimated amortization expense for each of the five succeeding years and periods thereafter is as follows (in thousands):



(In thousands)
Year Ending March 31,	Amount
2020	19,642
2021	19,646
2022	19,644
2023	19,644
2024	19,614
Thereafter	135,829
	$	234,019

Long-Term Debt

12 Months Ended

Mar. 31, 2019

Debt Disclosure [Abstract]

Long-Term Debt

2012 Term Loan and 2012 ABL Revolver:

On January 31, 2012, the Borrower entered into a senior secured credit facility, which consists of (i) a $660.0 million term loan facility (the “2012 Term Loan”) with a 7-year maturity and (ii) a $50.0 million asset-based revolving credit facility (the “2012 ABL Revolver”) with a 5-year maturity. In subsequent years, we have utilized portions of our accordion feature to increase the amount of our borrowing capacity under the 2012 ABL Revolver by $85.0 million to $135.0 million and reduced our borrowing rate on the 2012 ABL Revolver by 0.25% (discussed below). The 2012 Term Loan was issued with an original issue discount of 1.5% of the principal amount thereof, resulting in net proceeds to the Borrower of $650.1 million. The 2012 Term Loan is unconditionally guaranteed by Prestige Consumer Healthcare Inc. and certain of its domestic 100% owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company.

On February 21, 2013, we entered into Amendment No. 1 ("Term Loan Amendment No. 1") to the 2012 Term Loan. Term Loan Amendment No. 1 provided for the refinancing of all of the Borrower's existing Term B Loans with new Term B-1 Loans (the "Term B-1 Loans"). The interest rate on the Term B-1 Loans under Term Loan Amendment No. 1 was based, at our option, on a LIBOR rate plus a margin of 2.75% per annum, with a LIBOR floor of 1.00%, or an alternate base rate, with a floor of 2.00%, plus a margin. In addition, Term Loan Amendment No. 1 provided the Borrower with certain additional capacity to prepay subordinated debt, the 2012 Senior Notes and certain other unsecured indebtedness permitted to be incurred under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver.

On September 3, 2014, we entered into Amendment No. 2 ("Term Loan Amendment No. 2") to the 2012 Term Loan. Term Loan Amendment No. 2 provided for (i) the creation of a new class of Term B-2 Loans under the 2012 Term Loan (the "Term B-2 Loans") in an aggregate principal amount of $720.0 million, (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver, including additional investment, restricted payment and debt incurrence flexibility and financial maintenance covenant relief, and (iii) an interest rate on (x) the Term B-1 Loans that was based, at our option, on a LIBOR rate plus a margin of 3.125% per annum, with a LIBOR floor of 1.00%, or an alternate base rate, with a floor of 2.00%, plus a margin, and (y) the Term B-2 Loans that was based, at our option, on a LIBOR rate plus a margin of 3.50% per annum, with a LIBOR floor of 1.00%, or an alternate base rate, with a floor of 2.00%, plus a margin (with a margin step-down to 3.25% per annum, based upon achievement of a specified secured net leverage ratio).

Also on September 3, 2014, we entered into Amendment No. 3 ("ABL Amendment No. 3") to the 2012 ABL Revolver. ABL Amendment No. 3 provided for (i) a $40.0 million increase in revolving commitments under the 2012 ABL Revolver and (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver, including additional investment, restricted payment and debt incurrence flexibility. Borrowings under the 2012 ABL Revolver, as amended, bear interest at a rate per annum equal to an applicable margin, plus, at our option, either (i) a base rate determined by reference to the highest of (a) the Federal Funds rate plus 0.50%, (b) the prime rate of Citibank, N.A., and (c) the LIBOR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00% or (ii) a LIBOR rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing, adjusted for certain additional costs. The applicable margin for borrowings under the 2012 ABL Revolver may be increased to 2.00% or 2.25% for LIBOR borrowings and 1.00% or 1.25% for base-rate borrowings, depending on average excess availability under the 2012 ABL Revolver during the prior fiscal quarter. In addition to paying interest on outstanding principal under the 2012 ABL Revolver, we are required to pay a commitment fee to the lenders under the 2012 ABL Revolver in respect of the unutilized commitments thereunder. The initial commitment fee rate is 0.50% per annum. The commitment fee rate will be reduced to 0.375% per annum at any time when the average daily unused commitments for the prior quarter is less than a percentage of total commitments by an amount set forth in the credit agreement covering the 2012 ABL Revolver. We may voluntarily repay outstanding loans under the 2012 ABL Revolver at any time without a premium or penalty.

On May 8, 2015, we entered into Amendment No. 3 ("Term Loan Amendment No. 3") to the 2012 Term Loan. Term Loan Amendment No. 3 provided for (i) the creation of a new class of Term B-3 Loans under the 2012 Term Loan (the "Term B-3 Loans") in an aggregate principal amount of $852.5 million, which combined the outstanding balances of the Term B-1 Loans of $207.5 million and the Term B-2 Loans of $645.0 million, and (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver, including additional investment, restricted payment, and debt incurrence flexibility and financial maintenance covenant relief. The maturity date of the Term B-3 Loans remained the same as the Term B-2 Loans' original maturity date of September 3, 2021.

On June 9, 2015, we entered into Amendment No. 4 (“ABL Amendment No. 4”) to the 2012 ABL Revolver. ABL Amendment No. 4 provided for (i) a $35.0 million increase in the accordion feature under the 2012 ABL Revolver and (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and the 2012 ABL Revolver, including additional investment, restricted payment, and debt incurrence flexibility and financial maintenance covenant relief and (iii) extended the maturity date of the 2012 ABL Revolver to June 9, 2020, which is five years from the effective date of ABL Amendment No. 4.

In connection with the DenTek acquisition on February 5, 2016, we entered into Amendment No. 5 (“ABL Amendment No. 5”) to the 2012 ABL Revolver. ABL Amendment No. 5 temporarily suspended certain financial and related reporting covenants in the 2012 ABL Revolver until the earliest of (i) the date that was 60 calendar days following February 4, 2016, (ii) the date upon which certain of DenTek’s assets were included in the Company’s borrowing base under the 2012 ABL Revolver and (iii) the date upon which the Company received net proceeds from an offering of debt securities.

In connection with the Fleet acquisition, on January 26, 2017, we entered into Amendment No. 4 ("Term Loan Amendment No. 4") to the 2012 Term Loan. Term Loan Amendment No. 4 provided for (i) the refinancing of all of our outstanding term loans and the creation of a new class of Term B-4 Loans under the 2012 Term Loan (the "Term B-4 Loans") in an aggregate principal amount of $1,427.0 million and (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and the 2012 ABL Revolver, including additional investment, restricted payment, and debt incurrence flexibility and financial maintenance covenant relief. In addition, Citibank, N.A. was succeeded by Barclays Bank PLC as administrative agent under the 2012 Term Loan.

Also on January 26, 2017, we entered into Amendment No. 6 ("ABL Amendment No. 6") to the 2012 ABL Revolver. ABL Amendment No. 6 provides for (i) a $40.0 million increase in revolving commitments under the 2012 ABL Revolver, (ii) an extension of the maturity date of revolving commitments to January 26, 2022, and (iii) increased flexibility under the credit agreement governing the 2012 Term Loan and the 2012 ABL Revolver, including additional investment, restricted payment and debt incurrence flexibility consistent with Term Loan Amendment No. 4. We may voluntarily repay outstanding loans under the 2012 ABL Revolver at any time without a premium or penalty.

On March 21, 2018, we entered into Amendment No. 5 (“Term Loan Amendment No. 5”) to the 2012 Term Loan. Term Loan Amendment No. 5 ("Term B-5 Loans") provided for the repricing of the Term B-4 Loans under the Credit Agreement to an interest rate that is based, at our option, on a LIBOR rate plus a margin of 2.00% per annum, with a LIBOR floor of 0.00%, or an alternative base rate plus a margin of 1.00% per annum with a floor of 1.00%.

For the year ended March 31, 2019, the average interest rate on the 2012 Term Loan was 4.9% and the average interest rate on the amounts borrowed under the 2012 ABL Revolver was 3.8%.

2013 Senior Notes:

On December 17, 2013, the Borrower issued $400.0 million of senior unsecured notes, with an interest rate of 5.375% and a maturity date of December 15, 2021 (the "2013 Senior Notes"). The Borrower may redeem some or all of the 2013 Senior Notes at redemption prices set forth in the indenture governing the 2013 Senior Notes. The 2013 Senior Notes are guaranteed by Prestige Consumer Healthcare Inc. and certain of its 100% domestic owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company.

2016 Senior Notes:

On February 19, 2016, the Borrower completed the sale of $350.0 million aggregate principal amount of 6.375% senior notes due March 1, 2024 (the “Initial Notes”), pursuant to a purchase agreement, dated February 16, 2016, among the Borrower, the guarantors party thereto (the “Guarantors”) and the initial purchasers party thereto. The 2016 Senior Notes are guaranteed by Prestige Consumer Healthcare Inc. and certain of its domestic 100% owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the Guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company.

The 2016 Senior Notes were issued pursuant to an indenture, dated February 19, 2016 (the “Indenture”). The Indenture provides, among other things, that interest will be payable on the 2016 Senior Notes on March 1 and September 1 of each year, beginning on September 1, 2016, until their maturity date of March 1, 2024. The 2016 Senior Notes are senior unsecured obligations of the Borrower.

On March 21, 2018, we completed the sale of $250.0 million aggregate principal amount of 6.375% senior notes due 2024 (the “Additional Notes”), at an issue price of 101.0%, pursuant to a purchase agreement, dated March 16, 2018, among Prestige Consumer Healthcare Inc., the guarantors party thereto and the initial purchasers party thereto. The Additional Notes are senior unsecured obligations of Prestige Consumer Healthcare Inc. and are guaranteed by each of Prestige Consumer Healthcare's domestic subsidiaries that guarantee its obligations under the 2012 Term Loan. We used the proceeds from the issuance of the Additional Notes to repay a portion of our outstanding obligations under the 2012 Term Loan and to pay related fees and expenses. The Additional Notes will be treated as a single series with the $350.0 million aggregate principle amount of Initial Notes (the Initial Notes and, together with the Additional Notes, the “2016 Senior Notes”).

Redemptions and Restrictions:

On or after December 15, 2016, we have had the option to redeem some or all of the 2013 Senior Notes at redemption prices set forth in the indenture governing the 2013 Senior Notes. Subject to certain limitations, in the event of a change of control (as defined in the indenture governing the 2013 Senior Notes), the Borrower will be required to make an offer to purchase the 2013 Senior Notes at a price equal to 101% of the aggregate principal amount of the 2013 Senior Notes repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.

We have the option to redeem all or a portion of the 2016 Senior Notes at any time on or after March 1, 2019 at the redemption prices set forth in the Indenture, plus accrued and unpaid interest, if any. Subject to certain limitations, in the event of a change of control (as defined in the Indenture), we will be required to make an offer to purchase the 2016 Senior Notes at a price equal to 101% of the aggregate principal amount of the notes repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.

The indentures governing the 2013 Senior Notes and the 2016 Senior Notes contain provisions that restrict us from undertaking specified corporate actions, such as asset dispositions, acquisitions, dividend payments, repurchases of common shares outstanding, changes of control, incurrences of indebtedness, issuance of equity, creation of liens, making of loans and transactions with affiliates. Additionally, the credit agreement governing the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2013 Senior Notes and the 2016 Senior Notes contain cross-default provisions, whereby a default pursuant to the terms and conditions of certain indebtedness will cause a default on the remaining indebtedness under the credit agreement governing the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2013 Senior Notes and the 2016 Senior Notes. At March 31, 2019, we were in compliance with the covenants under our long-term indebtedness.

At March 31, 2019, we had an aggregate of $0.8 million of unamortized debt costs related to the 2012 ABL Revolver included in other long-term assets, and $14.4 million of unamortized debt costs included in long-term debt costs, the total of which is comprised of $2.8 million related to the 2013 Senior Notes, $4.3 million related to the 2016 Senior Notes, and $7.3 million related to the 2012 Term Loan.

At March 31, 2018 we had an aggregate of $1.1 million of unamortized debt costs related to the 2012 ABL Revolver included in other long-term assets, and $20.0 million of unamortized debt costs included in long-term debt costs, the total of which is comprised of $3.7 million related to the 2013 Senior Notes, $5.0 million related to the 2016 Senior Notes, and $11.3 million related to the 2012 Term Loan.

At March 31, 2019, we had $75.0 million outstanding on the 2012 ABL Revolver and a borrowing capacity of $95.6 million.

Long-term debt consists of the following, as of the dates indicated:



(In thousands, except percentages)	March 31, 2019			March 31, 2018
2016 Senior Notes bearing interest at 6.375%, with interest payable on March 1 and September 1 of each year. The 2016 Senior Notes mature on March 1, 2024.	$	600,000		$	600,000
2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year. The 2013 Senior Notes mature on December 15, 2021.	400,000			400,000
2012 Term B-5 Loans bearing interest at the Borrower's option at either LIBOR plus a margin of 2.00%, with a LIBOR floor of 0.00%, or an alternate base rate plus a margin of 1.00% with a floor of 1.00% due on January 26, 2024.	738,000			938,000
2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on January 26, 2022.	75,000			75,000
Long-term debt	1,813,000			2,013,000
Less: unamortized debt costs	(14,402		)	(20,048		)
Long-term debt, net	$	1,798,598		$	1,992,952

As of March 31, 2019, aggregate future principal payments required in accordance with the terms of the 2012 Term Loan, 2012 ABL Revolver and the indentures governing the 2016 Senior Notes and the 2013 Senior Notes are as follows:



(In thousands)
Year Ending March 31,	Amount
2020	$	—
2021	—
2022	475,000
2023	—
2024	1,338,000
Thereafter	—
	$	1,813,000

Fair Value Measurements

12 Months Ended

Mar. 31, 2019

Fair Value Disclosures [Abstract]

Fair Value Measurements

For certain of our financial instruments, including cash, accounts receivable, accounts payable and other current liabilities, the carrying amounts approximate their respective fair values due to the relatively short maturity of these amounts.

The Fair Value Measurements and Disclosures topic of the FASB ASC 820 requires fair value to be determined based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market assuming an orderly transaction between market participants. The Fair Value Measurements and Disclosures topic established market (observable inputs) as the preferred source of fair value, to be followed by the Company's assumptions of fair value based on hypothetical transactions (unobservable inputs) in the absence of observable market inputs. Based upon the above, the following fair value hierarchy was created:

Level 1 - Quoted market prices for identical instruments in active markets;

Level 2 - Quoted prices for similar instruments in active markets, as well as quoted prices for identical or similar instruments in markets that are not considered active; and

Level 3 - Unobservable inputs developed by the Company using estimates and assumptions reflective of those that would be utilized by a market participant.

The market values have been determined based on market values for similar instruments adjusted for certain factors. As such, the 2016 Senior Notes, the 2013 Senior Notes, the Term B-5 Loans, and the 2012 ABL Revolver are measured in Level 2 of the above hierarchy (see summary below detailing the carrying amounts and estimated fair values of these borrowings at March 31, 2019 and 2018).



	March 31, 2019				March 31, 2018
(In thousands)	Carrying Value		Fair Value		Carrying Value		Fair Value
2016 Senior Notes	$	600,000	$	606,000	$	600,000	$	610,500
2013 Senior Notes	400,000		401,500		400,000		402,000
2012 Term B-5 Loans	738,000		728,775		938,000		939,173
2012 ABL Revolver	75,000		75,000		75,000		75,000

At March 31, 2019 and 2018, we did not have any assets or liabilities measured in Level 1 or 3. During 2019, 2018 and 2017, there were no transfers of assets or liabilities between Levels 1, 2 and 3.

In accordance with ASU 2015-07, Fair Value Measurement (Topic 820): Disclosures for Investments in Certain Entities That Calculate Net Asset Value per Share (or Its Equivalent), investments that are measured at fair value using net asset value ("NAV") per share as a practical expedient have not been classified in the fair value hierarchy.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Stockholders' Equity	12 Months Ended
Stockholders' Equity	Mar. 31, 2019
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders' Equity The Company is authorized to issue 250.0 million shares of common stock, $0.01 par value per share, and 5.0 million shares of preferred stock, $0.01 par value per share. The Board of Directors may direct the issuance of the undesignated preferred stock in one or more series and determine preferences, privileges and restrictions thereof. Each share of common stock has the right to one vote on all matters submitted to a vote of stockholders. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared or paid on the Company's common stock through March 31, 2019. During the years ended March 31, 2019 and 2018, we repurchased 68,939 shares and 20,549 shares, respectively, of common stock from our employees pursuant to the provisions of the various employee restricted stock awards. The repurchases during the years ended March 31, 2019 and 2018 were at an average price of $33.09 and $52.33, respectively. All of the repurchased shares have been recorded as treasury stock. During the year ended March 31, 2019, we also repurchased 1,449,750 shares of our common stock in conjunction with our share repurchase program. The repurchases were at an average price of $34.47 per share, totaled $50.0 million, and have been recorded as treasury stock.

Share-Based Compensation

12 Months Ended

Mar. 31, 2019

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share-Based Compensation

In connection with our initial public offering, the Board of Directors adopted the 2005 Long-Term Equity Incentive Plan (the “Plan”), which provides for grants of up to a maximum of 5.0 million shares of restricted stock, stock options, RSUs and other equity-based awards. In June 2014, the Board of Directors approved, and in July 2014, the stockholders ratified, an increase of an additional 1.8 million shares of our common stock for issuance under the Plan, an increase of the maximum number of shares subject to stock options that may be awarded to any one participant under the Plan during any fiscal 12-month period from 1.0 million to 2.5 million shares, and an extension of the term of the Plan by ten years, to February 2025. Directors, officers and other employees of the Company and its subsidiaries, as well as others performing services for the Company, are eligible for grants under the Plan.

During 2019, pre-tax share-based compensation costs charged against income and the related income tax benefit recognized were $7.4 million and $1.4 million, respectively.

During 2018, pre-tax share-based compensation costs charged against income and the related income tax benefit recognized were $8.9 million and $1.8 million, respectively.

During 2017, pre-tax share-based compensation costs charged against income and the related income tax benefit recognized were $8.1 million and $2.6 million, respectively.

At March 31, 2019, there were $5.5 million of unrecognized compensation costs related to nonvested share-based compensation arrangements under the Plan, based on management’s estimate of the shares that will ultimately vest. We expect to recognize such costs over a weighted-average period of 0.9 years. The total fair value of options and restricted shares vested during 2019, 2018, and 2017 was $12.0 million, $6.8 million and $6.0 million, respectively. Cash received from the exercise of stock options was $2.9 million during 2019, and we realized $1.3 million in tax benefits for the tax deductions resulting from RSU issuances and option exercises in 2019. Cash received from the exercise of stock options was $1.6 million during 2018, and we realized $1.1 million in tax benefits for the tax deductions resulting from RSU issuances and option exercises in 2018. Cash received from the exercise of stock options was $4.0 million during 2017, and we realized $2.0 million in tax benefits for the tax deductions from RSU issuances and option exercises in 2017. At March 31, 2019, there were 1.8 million shares available for issuance under the Plan.

On May 7, 2018, the Compensation and Talent Management Committee of our Board of Directors granted 103,406 performance units, 100,399 RSUs and stock options to acquire 294,484 shares of our common stock to certain executive officers and employees under the Plan. The stock options were granted at an exercise price of $29.46 per share, which was equal to the closing price for our common stock on the date of the grant.

Pursuant to the Plan, each of the independent members of the Board of Directors received a grant of 3,779 RSUs on July 31, 2018. The RSUs are fully vested upon receipt of the award and will be settled by delivery to the director of one share of common stock of the Company for each vested RSU promptly following the earliest of the director's (i) death, (ii) disability or (iii) the six-month anniversary of the date on which the director's Board membership ceases for reasons other than death or disability.

Restricted Stock Units

Restricted stock units granted to employees under the Plan generally vest in three years, primarily upon the attainment of certain time vesting thresholds, and, in the case of performance share units, may also be contingent on the attainment of certain performance goals of the Company, including revenue and earnings before income taxes, depreciation and amortization targets. The RSUs provide for accelerated vesting if there is a change of control, as defined in the Plan. The RSUs granted to employees generally vest either ratably over three years or in their entirety on the three-year anniversary of the date of the grant. Upon vesting, the units will be settled in shares of our common stock. Termination of employment prior to vesting will result in forfeiture of the RSUs, unless otherwise accelerated by the Compensation and Talent Management Committee or, in the case of RSUs granted in May 2017 and 2018, subject to pro-rata vesting in the event of death, disability or retirement. The RSUs granted to directors vest immediately upon grant, and will be settled by delivery to the director of one share of common stock of the Company for each vested RSU promptly following the earliest of the director's (i) death, (ii) disability or (iii) six-month anniversary of the date on which the director's Board membership ceases for reasons other than death or disability.

The fair value of the RSUs is determined using the closing price of our common stock on the date of the grant.

A summary of the Company’s RSUs granted under the Plan is presented below:



RSUs	Shares (in thousands)		Weighted-Average Grant-Date Fair Value
Vested and nonvested at March 31, 2016	467.8		$	35.22

Granted	68.4		55.44
Vested and issued	(94.7	)	28.51
Forfeited	(91.4	)	41.71
Vested and nonvested at March 31, 2017	350.1		39.29
Vested at March 31, 2017	63.4		20.12

Granted	105.8		55.61
Vested and issued	(53.3	)	34.30
Forfeited	(9.1	)	48.76
Vested and nonvested at March 31, 2018	393.5		44.13
Vested at March 31, 2018	90.5		29.88

Granted	226.4		30.09
Vested and issued	(175.8	)	43.05
Forfeited	(31.1	)	48.32
Vested and nonvested at March 31, 2019	413.0		36.58
Vested at March 31, 2019	113.2		31.05

Options

The Plan provides that the exercise price of options granted shall be no less than the fair market value of the Company's common stock on the date the options are granted. Options granted have a term of no greater than ten years from the date of grant and vest in accordance with a schedule determined at the time the option is granted, generally three to five years. The option awards provide for accelerated vesting in the event of a change in control, as defined in the Plan. Except in the case of death, disability or retirement, termination of employment prior to vesting will result in forfeiture of the unvested stock options. Vested stock options will remain exercisable by the employee after termination of employment, subject to the terms in the Plan.

The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions noted in the table below. Expected volatilities are based on the historical volatility of our common stock and other factors, including the historical volatilities of comparable companies. We use appropriate historical data, as well as current data, to estimate option exercise and employee termination behaviors. Employees that are expected to exhibit similar exercise or termination behaviors are grouped together for the purposes of valuation. The expected terms of the options granted are derived from our historical experience, management’s estimates, and consideration of information derived from the public filings of companies similar to us, and represent the period of time that options granted are expected to be outstanding. The risk-free rate represents the yield on U.S. Treasury bonds with a maturity equal to the expected term of the granted options.

The weighted-average grant-date fair values of the options granted during 2019, 2018, and 2017 were $10.22, $21.20, and $21.75, respectively.



	Year Ended March 31,
	2019		2018		2017
Expected volatility	29.6	%	35.2	%	37.8	%
Expected dividends	—		—		—
Expected term in years	6.0		6.0		6.0
Risk-free rate	2.9	%	2.2	%	1.7	%

A summary of option activity under the Plan is as follows:



Options	Shares (in thousands)		Weighted-Average Exercise Price		Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value (in thousands)

Outstanding at March 31, 2016	727.7		$	30.70

Granted	264.3		55.86
Exercised	(126.8	)	31.75
Forfeited or expired	(92.9	)	42.66
Outstanding at March 31, 2017	772.3		37.70

Granted	182.8		56.11
Exercised	(55.7	)	29.08
Forfeited or expired	(26.2	)	48.19
Outstanding at March 31, 2018	873.2		41.79

Granted	294.5		29.46
Exercised	(97.7	)	30.02
Forfeited or expired	(125.4	)	47.16
Outstanding at March 31, 2019	944.6		38.45		7.0	$	2,048
Exercisable at March 31, 2019	499.4		37.87		5.5	$	1,921

The aggregate intrinsic value of options exercised during 2019, 2018 and 2017 was $0.8 million, $1.2 million and $3.2 million, respectively.

Employee Retirement Plans

12 Months Ended

Mar. 31, 2019

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Employee Retirement Plans

We have a defined contribution plan in which all U.S. full-time employees are eligible to participate. The participants may contribute from 1% to 70% of their compensation, as defined in the plan. We match 100% of the first 3%, plus 50% of the next 3%, of each participant's base compensation with full vesting immediately. We may also make additional contributions to the plan as determined by the Board of Directors. The total expense for the defined contribution plan was $1.5 million, $1.6 million and $0.9 million for 2019, 2018 and 2017, respectively.

Certain employees of Fleet are covered by defined benefit pension plans. The Company’s policy is to contribute at least the minimum amount required under ERISA. The Company may elect to make additional contributions. Benefits are based on years of service and levels of compensation. On December 16, 2014, the decision was made to freeze the benefits under the Company's U.S. qualified defined benefit pension plan with an effective date of March 1, 2015.

Benefit Obligations and Plan Assets

The following table summarizes the changes in the U.S. pension plan obligations and plan assets and includes a statement of the plans' funded status as of March 31, 2019 and 2018:



	March 31,
(In thousands)	2019			2018
Change in benefit obligation:
Projected benefit obligation at beginning of period	$	61,882		$	61,714
Interest cost	2,380			2,529
Actuarial (gain) loss	(744		)	800
Benefits paid	(3,184		)	(3,161		)
Projected benefit obligations at end of year	$	60,334		$	61,882

Change in plan assets:
Fair value of plan assets at beginning of period	$	50,508		$	47,772
Actual return on plan assets	2,416			5,505
Employer contribution	1,375			392
Benefits paid	(3,184		)	(3,161		)
Fair value of plan assets at end of year	$	51,115		$	50,508

Funded status at end of year	$	(9,219	)	$	(11,374	)

Amounts recognized in the balance sheet at the end of the period consist of the following:



	March 31,
(In thousands)	2019		2018
Current liability	$	361	461
Long-term liability	8,858		10,913
Total	$	9,219	$	11,374

The primary components of Net Periodic Benefits consist of the following:



	Year Ended March 31,
(In thousands)	2019			2018			2017
Interest cost	$	2,380		$	2,529		$	456
Expected return on assets	(3,070		)	(2,901		)	(462		)
Net periodic benefit cost (income)	$	(690	)	$	(372	)	$	(6	)

The accumulated benefit obligation, which represents benefits earned to the measurement date, was $60.3 million at March 31, 2019, and $61.9 million at March 31, 2018 and we had a net periodic benefit (income) of less than $1.0 million for 2019, 2018 and 2017.

The pension benefit amounts stated above include one pension plan that is an unfunded plan. The projected benefit obligation and accumulated benefit obligation for this unfunded plan were $4.6 million as of March 31, 2019 and $5.9 million as of March 31, 2018.

The following table includes amounts that are expected to be contributed to the plans by the Company. It reflects benefit payments that are made from the plans' assets as well as those made directly from the Company's assets. The amounts in the table are actuarially determined and reflect the Company's best estimate given its current knowledge; actual amounts could be materially different.



(In thousands)	Pension Benefits
Employer contributions:
2020 (expectation) to participant benefits	$	1,361

Expected benefit payments year ending March 31,
2020	$	3,371
2021	3,472
2022	3,592
2023	3,678
2024	3,743
2025-2029	18,771

During 2019, we made a $1.0 million contribution to the qualified defined benefit plan. During 2018, we made no contribution to the qualified plan. During 2017, we funded $6.0 million to the plan.

The Company's primary investment objective for its qualified pension plan assets is to provide a source of retirement income for the plans' participants and beneficiaries. The asset allocation for the Company's funded retirement plan as of March 31, 2019 and 2018, and the target allocation by asset category are as follows:



	Percentage of Plan Assets
Asset Category	Target Allocation		March 31, 2019		March 31, 2018
Domestic large cap equities	18	%	18	%	21	%
Domestic small/mid cap equities	5		5		6
International equities	15		15		18
Fixed income and cash	62		62		55
Total	100	%	100	%	100	%

The plan assets are invested in a diversified portfolio consisting primarily of domestic fixed income and publicly traded equity securities held within group trust funds at March 31, 2019 and 2018. These assets are fair valued using NAV.

The following tables show the unrecognized actuarial loss (gain) included in accumulated other comprehensive income at March 31, 2019, 2018 and 2017, as well as the prior service cost credit and actuarial loss expected to be reclassified from accumulated other comprehensive income (loss) to retirement expense during 2020:



(In thousands)
Balances in accumulated other comprehensive loss as of March 31, 2017:
Unrecognized actuarial loss	$	399
Unrecognized prior service credit	—

Balances in accumulated other comprehensive loss as of March 31, 2018:
Unrecognized actuarial (gain)	$	(1,407	)
Unrecognized prior service credit	—

Balances in accumulated other comprehensive (income) as of March 31, 2019:
Unrecognized actuarial (gain)	$	(1,469	)
Unrecognized prior service credit	—

Amounts expected to be reclassified from accumulated other comprehensive income (loss) during 2020:
Unrecognized actuarial (loss)	$	—
Unrecognized prior service credit	—

Assumptions used in determining the actuarial present value of the benefit obligation as of March 31, 2019 and 2018 were as follows:



	March 31,
	2019	2018
Key assumptions:
Discount rate	3.80% to 3.99%	3.93% to 4.07%
Expected return on plan assets, net of administrative fees	5.75%	6.25%
Rate of compensation increase	—	—

The determination of the expected long-term rate of return was derived from an optimized portfolio using an asset allocation software program. The risk and return assumptions, along with the correlations between the asset classes, were entered into the program. Based on these assumptions and historical experience, the portfolio is expected to achieve a long-term rate of return of 5.75%. The investment managers engaged to manage the portfolio are expected to outperform their expected benchmarks on a relative basis over a full market cycle.

Income Taxes

12 Months Ended

Mar. 31, 2019

Income Tax Disclosure [Abstract]

Income Taxes

On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Act. The Tax Act represented significant U.S. federal tax reform legislation that included a permanent reduction to the U.S. federal corporate income tax rate. The permanent reduction to the federal corporate income tax rate resulted in a one-time benefit of $267.0 million related to the value of our deferred tax liabilities and a benefit of $3.2 million related to the lower blended tax rate on our earnings, in the year ended March 31, 2018, resulting in a net benefit of $270.2 million. Additionally, the tax reform legislation subjects certain of our cumulative foreign earnings and profits to U.S. income taxes through a deemed repatriation, which resulted in a charge of $1.9 million in the year ended March 31, 2018.

Income (loss) before income taxes consists of the following:



	Year Ended March 31,
(In thousands)	2019			2018		2017
United States	$	(52,313	)	$	84,435	$	93,582
Foreign	14,258			22,651		17,268
	$	(38,055	)	$	107,086	$	110,850

The (benefit) provision for income taxes consists of the following:



	Year Ended March 31,
(In thousands)	2019			2018			2017
Current
Federal	$	27,629		$	31,327		$	40,183
State	3,156			2,686			2,808
Foreign	7,193			5,588			4,242
Deferred
Federal	(35,760		)	(270,796		)	(5,421		)
State	(4,101		)	(1,240		)	(163		)
Foreign	(372		)	(49		)	(194		)
Total (benefit) provision for income taxes	$	(2,255	)	$	(232,484	)	$	41,455

The principal components of our deferred tax balances are as follows:



	March 31,
(In thousands)	2019			2018
Deferred Tax Assets
Allowance for doubtful accounts and sales returns	$	3,285		$	2,806
Inventory capitalization	1,245			1,176
Inventory reserves	1,267			540
Net operating loss carryforwards	226			609
State income taxes	9,003			10,154
Accrued liabilities	1,785			2,210
Accrued compensation	4,416			4,992
Stock compensation	4,206			5,038
Foreign tax credit	3,236			—
Interest	154			—
Other	7,691			4,975
Total deferred tax assets	$	36,514		$	32,500

Deferred Tax Liabilities
Property, plant and equipment	$	(6,002	)	$	(6,032	)
Intangible assets	(425,134		)	(467,388		)
Adoption of revenue recognition standard	(721		)	—
Total deferred tax liabilities	$	(431,857	)	$	(473,420	)

Net deferred tax liability before valuation allowance	$	(395,343	)	$	(440,920	)
Valuation allowance	(3,236		)	(609		)
Net deferred tax liability	$	(398,579	)	$	(441,529	)

The net deferred tax liability shown above is net of $1.0 million of long-term deferred tax assets as of March 31, 2019 and $1.0 million of long-term deferred tax assets as of March 31, 2018.

At March 31, 2019 and 2018, we have a valuation allowance of $3.2 million and $0.6 million, respectively, related to certain deferred tax assets that we have concluded are not more likely than not to be realized. The increase in the valuation allowance related to unutilized foreign tax credit carryovers, as further described below.

A reconciliation of the effective tax rate compared to the statutory U.S. Federal tax rate is as follows:



	Year Ended March 31,
	2019					2018					2017
(In thousands)				%					%					%
Income tax (benefit) provision at statutory rate	$	(7,992	)	21.0		$	37,480		35.0		$	38,798		35.0
Foreign tax provision (benefit)	2,866			(7.5	)	(2,084		)	(1.9	)	(2,322		)	(2.1	)
State income taxes, net of federal income tax benefit	(1,710		)	4.5		1,414			1.3		1,820			1.7
Impact of tax legislation	—			—		(268,244		)	(250.5	)	—			—
Goodwill impairment	5,616			(14.8	)	—			—		3,208			2.9
R&D	(629		)	1.7		—			—		—			—
Compensation limitations	296			(0.8	)	—			—		—			—
Valuation allowance	2,627			(6.9	)	(2,828		)	(2.6	)	—			—
Gain on sale	1,312			(3.4	)	—			—		—			—
Nondeductible transaction costs	—			—		—			—		686			0.6
Nondeductible compensation	—			—		—			—		342			0.3
Other	(4,641		)	12.1		1,778			1.6		(1,077		)	(1.0	)
Total (benefit) provision for income taxes	$	(2,255	)	5.9		$	(232,484	)	(217.1	)	$	41,455		37.4

Uncertain tax liability activity is as follows:



	2019			2018			2017
(In thousands)
Balance – beginning of year	$	10,827		$	3,651		$	4,084
Additions based on tax positions related to the current year	585			7,286			583
Reductions based on lapse of statute of limitations	(650		)	(110		)	(1,016		)
Payments and other movements	(888		)	—			—
Balance – end of year	$	9,874		$	10,827		$	3,651

We recognize interest and penalties related to uncertain tax positions as a component of income tax (benefit) expense. We did not incur any material interest or penalties related to income taxes in 2019, 2018 or 2017. We do not anticipate any events or circumstances that would cause a significant change to these uncertainties during the ensuing year. We are subject to taxation in the United States and various state and foreign jurisdictions, and we are generally open to examination from the year ended March 31, 2016 forward.

In January 2018, the FASB released guidance on the accounting for tax on the global intangible low-taxed income (“GILTI”) provisions of the Tax Act. The GILTI provisions impose a tax on foreign income in excess of a deemed return on tangible assets of foreign corporations. Pursuant to the FASB guidance, we elected to treat any potential GILTI inclusions as a period cost without recognizing any related potential deferred tax liabilities or assets.

Our current foreign tax credit analysis is suggestive of annual foreign tax credit limitation anticipated to be less than foreign income taxes accrued during the year. The operating conditions giving rise to such excess credit condition may be anticipated to continue into future tax years. As a result, we have recognized a full valuation allowance for the deferred tax asset recognized in respect of unutilized foreign tax credit carryovers, which are limited to ten-year carryovers under IRC §904(c). Such excess credit condition did not exist in prior years; however, the Tax Act, enacted in 2017, required substantial changes in the manner of calculating foreign tax credit limitation.

Commitments and Contingencies

12 Months Ended

Mar. 31, 2019

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

We are involved from time to time in routine legal matters and other claims incidental to our business. We review outstanding claims and proceedings internally and with external counsel as necessary to assess probability and amount of potential loss. These assessments are re-evaluated at each reporting period and as new information becomes available to determine whether a reserve should be established or if any existing reserve should be adjusted. The actual cost of resolving a claim or proceeding ultimately may be substantially different than the amount of the recorded reserve. In addition, because it is not permissible under GAAP to establish a litigation reserve until the loss is both probable and estimable, in some cases there may be insufficient time to establish a reserve prior to the actual incurrence of the loss (upon verdict and judgment at trial, for example, or in the case of a quickly negotiated settlement). We believe the resolution of routine legal matters and other claims incidental to our business, taking our reserves into account, will not have a material adverse effect on our business, financial condition, or results of operations.

Lease Commitments

We have operating leases for office facilities and equipment, including New York and other locations, which expire at various dates through fiscal 2028. These amounts have been included in the table below.

The following summarizes future minimum lease payments for our operating leases as of March 31, 2019 ^(a):



(In thousands)	Facilities		Equipment		Total
Year Ending March 31,
2020	$	2,828	$	314	$	3,142
2021	2,633		248		2,881
2022	2,265		213		2,478
2023	1,684		105		1,789
2024	1,705		—		1,705
Thereafter	6,780		—		6,780
	$	17,895	$	880	$	18,775

(a) Minimum lease payments have not been reduced by minimum sublease rentals of $0.5 million due in the future under non- cancellable subleases.

The following schedule shows the composition of total minimum lease payments that have been reduced by minimum sublease rentals:



	Year ending March 31,
(In thousands)	2019			2018
Minimum lease payments	$	18,775		$	20,987
Less: Sublease rentals	(509		)	(1,018		)
	$	18,266		$	19,969

Rent expense was $2.4 million, $1.9 million, and $2.0 million for 2019, 2018, and 2017, respectively.

Purchase Commitments

We have supply agreements for the manufacture of some of our products. The following table shows the minimum amounts that we are committed to pay under these agreements:



(In thousands)
Year Ending March 31,	Amount
2020	$	9,802
2021	9,719
2022	9,497
2023	1,650
2024	—
Thereafter	—
	$	30,668

Concentrations of Risk	12 Months Ended
Concentrations of Risk	Mar. 31, 2019
Risks and Uncertainties [Abstract]
Concentrations of Risk	Concentrations of Risk Our revenues are concentrated in the areas of OTC Healthcare and Household Cleaning products (prior to the sale of our Household Cleaning segment, as discussed in Note 3). We sell our products to mass merchandisers and drug, food, dollar, convenience and club stores and ecommerce channels. During 2019, 2018, and 2017, approximately 42.9%, 41.2%, and 40.0%, respectively, of our gross revenues were derived from our five top selling brands. One customer, Walmart, accounted for more than 10% of our gross revenues for each of the periods presented. During 2019, 2018, and 2017, Walmart accounted for approximately 23.7%, 23.8%, and 21.1%, respectively, of our gross revenues. At March 31, 2019, approximately 25.1% of our accounts receivable were owed by Walmart. Our product distribution in the United States is currently managed by a third party through one primary distribution center near St. Louis, Missouri, and we operate one manufacturing facility for certain of our products located in Lynchburg, Virginia. On May 13, 2019, we entered into an agreement with a second third party logistics provider for a warehouse, and we intend to transition to this facility, which will be managed by a new logistics provider. A serious disruption, caused by performance or contractual issues with a third party distribution manager or by earthquake, flood, or fire, could damage our inventory and/or materially impair our ability to distribute our products to customers in a timely manner or at a reasonable cost. Any disruption as a result of business integration, transition of our distribution center to the new third party manager or new location, or third party performance at our distribution centers could result in increased costs, expense and/or shipping times, and could cause us to incur customer fees and penalties. In addition, any serious disruption to our Lynchburg manufacturing facility could materially impair our ability to manufacture many of the Fleet products, which would also limit our ability to provide those products to customers in a timely manner or at a reasonable cost. We could also incur significantly higher costs and experience longer lead times if we need to replace our distribution centers, the third party distribution managers or the manufacturing facility. As a result, any serious disruption could have a material adverse effect on our business, financial condition and results of operations. At March 31, 2019, we had relationships with 113 third party manufacturers. Of those, we had long-term contracts with 33 manufacturers that produced items that accounted for approximately 65.6% of our gross sales for 2019, compared to 46 manufacturers with long-term contracts that accounted for approximately 73.6% of gross sales in 2018. The fact that we do not have long-term contracts with certain manufacturers means that they could cease manufacturing our products at any time and for any reason or initiate arbitrary and costly price increases, which could have a material adverse effect on our business and results from operations. Although we are in the process of negotiating long-term contracts with certain key manufacturers, we may not be able to reach a timely agreement, which could have a material adverse effect on our business and results of operations.

Business Segments

12 Months Ended

Mar. 31, 2019

Segment Reporting [Abstract]

Business Segments

Segment information has been prepared in accordance with the Segment Reporting topic of FASB ASC 280. Our current reportable segments consist of (i) North American OTC Healthcare and (ii) International OTC Healthcare. We sold our Household Cleaning segment on July 2, 2018; see Note 3 for further information. We evaluate the performance of our operating segments and allocate resources to these segments based primarily on contribution margin, which we define as gross profit less advertising and promotional expenses.

The tables below summarize information about our operating and reportable segments.



	Year Ended March 31, 2019
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Total segment revenues*	$	862,446	$	93,520	$	19,811	$	975,777
Cost of sales	364,533		39,080		16,588		420,201
Gross profit	497,913		54,440		3,223		555,576
Advertising and promotion	126,374		16,286		430		143,090
Contribution margin	$	371,539	$	38,154	$	2,793	412,486
Other operating expenses**							344,983
Operating income							67,503
Other expense							105,558
Loss before income taxes							(38,055		)
Benefit for income taxes							(2,255		)
Net loss							$	(35,800	)

*Intersegment revenues of $7.4 million were eliminated from the North American OTC Healthcare segment.

**Other operating expenses for the year ended March 31, 2019 includes a tradename impairment charge of $195.9 million and a goodwill impairment charge of $33.5 million .



	Year Ended March 31, 2018
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Total segment revenues*	$	868,874	$	91,658	$	80,647	$	1,041,179
Cost of sales	357,298		40,244		67,132		464,674
Gross profit	511,576		51,414		13,515		576,505
Advertising and promotion	129,058		16,267		1,961		147,286
Contribution margin	$	382,518	$	35,147	$	11,554	429,219
Other operating expenses**							213,745
Operating income							215,474
Other expense							108,388
Income before income taxes							107,086
Provision for income taxes							(232,484		)
Net income							$	339,570

* Intersegment revenues of $7.7 million were eliminated from the North American OTC Healthcare segment.

**Other operating expenses for the year ended March 31, 2018 includes a tradename impairment charge of $99.9 million.



	Year Ended March 31, 2017
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Total segment revenues*	$	720,824	$	73,304	$	87,932	$	882,060
Cost of sales	282,750		30,789		68,235		381,774
Gross profit	438,074		42,515		19,697		500,286
Advertising and promotion	112,465		13,434		2,460		128,359
Contribution margin	$	325,609	$	29,081	$	17,237	371,927
Other operating expenses**							166,284
Operating income							205,643
Other expense							94,793
Income before income taxes							110,850
Provision for income taxes							41,455
Net income							$	69,395

*Intersegment revenues of $4.2 million were eliminated from the North America OTC Healthcare segment.

**Other operating expenses for the year ended March 31, 2017 includes a pre-tax net loss of $51.8 million related to divestitures. These divestitures include Pediacare®, New Skin®, Fiber Choice®, e.p.t®, Dermoplast®, and license rights in certain geographic areas pertaining to Comet®. The assets and corresponding contribution margin associated with the pre-tax net loss on divestitures related to Pediacare®, New Skin®, Fiber Choice®, e.p.t® and Dermoplast® are included within the North American OTC Healthcare segment, while the pre-tax gain on sale of license rights related to Comet® are included in the Household Cleaning segment.

The tables below summarize information about our segment revenues from similar product groups.



	Year Ended March 31, 2019
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	113,563	$	615	$	—	$	114,178
Cough & Cold	83,168		19,955		—		103,123
Women's Health	244,927		13,552		—		258,479
Gastrointestinal	125,416		35,046		—		160,462
Eye & Ear Care	101,128		11,709		—		112,837
Dermatologicals	95,801		2,171		—		97,972
Oral Care	92,964		10,468		—		103,432
Other OTC	5,479		4		—		5,483
Household Cleaning	—		—		19,811		19,811
Total segment revenues	$	862,446	$	93,520	$	19,811	$	975,777



	Year Ended March 31, 2018
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	118,610	$	807	$	—	$	119,417
Cough & Cold	93,537		18,310		—		111,847
Women's Health	247,244		12,140		—		259,384
Gastrointestinal	117,627		34,609		—		152,236
Eye & Ear Care	92,308		11,744		—		104,052
Dermatologicals	94,775		2,113		—		96,888
Oral Care	99,072		11,930		—		111,002
Other OTC	5,701		5		—		5,706
Household Cleaning	—		—		80,647		80,647
Total segment revenues	$	868,874	$	91,658	$	80,647	$	1,041,179



	Year Ended March 31, 2017
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	120,253	$	1,922	$	—	$	122,175
Cough & Cold	90,795		17,990		—		108,785
Women's Health	147,071		3,811		—		150,882
Gastrointestinal	76,500		24,812		—		101,312
Eye & Ear Care	97,618		12,075		—		109,693
Dermatologicals	85,194		2,159		—		87,353
Oral Care	97,586		10,513		—		108,099
Other OTC	5,807		22		—		5,829
Household Cleaning	—		—		87,932		87,932
Total segment revenues	$	720,824	$	73,304	$	87,932	$	882,060

Our total segment revenues by geographic area are as follows:



	Year Ended March 31,
	2019		2018		2017
United States	$	837,049	$	903,511	$	769,732
Rest of world	138,728		137,668		112,328
Total	$	975,777	$	1,041,179	$	882,060

Our consolidated goodwill and intangible assets have been allocated to the reportable segments as follows:



March 31, 2019 (In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Goodwill	$	547,393	$	31,190	$	—	$	578,583

Intangible assets
Indefinite-lived	2,195,617		77,574		—		2,273,191
Finite-lived	228,743		5,276		—		234,019
Intangible assets, net	$	2,424,360	82,850		—		2,507,210
Total	$	2,971,753	$	114,040	$	—	$	3,085,793



March 31, 2018 (In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Goodwill	$	580,934	$	32,919	$	6,245	$	620,098

Intangible assets
Indefinite-lived	2,375,736		84,006		30,561		2,490,303
Finite-lived	265,356		6,068		19,189		290,613
Intangible assets, net	2,641,092		90,074		49,750		2,780,916
Total	$	3,222,026	$	122,993	$	55,995	$	3,401,014

Our goodwill and intangible assets by geographic area are as follows:



	Year Ended March 31,
	2019		2018
United States	$	2,971,753	$	3,278,021
Rest of world	114,040		122,993
Total	$	3,085,793	$	3,401,014

Unaudited Quarterly Financial Information

12 Months Ended

Mar. 31, 2019

Quarterly Financial Information Disclosure [Abstract]

Unaudited Quarterly Financial Information

Unaudited quarterly financial information for 2019 and 2018 is as follows:

Year Ended March 31, 2019



	Quarterly Period Ended
(In thousands, except for per share data)	June 30, 2018			September 30, 2018			December 31, 2018			March 31, 2019
Total revenues	$	253,980		$	239,357		$	241,414		$	241,026
Cost of sales	113,357			101,885			102,179			102,780
Gross profit	140,623			137,472			139,235			138,246

Operating expenses
Advertising and promotion	37,111			37,042			34,504			34,433
General and administrative	23,941			24,034			20,485			21,299
Depreciation and amortization	7,084			6,756			6,705			6,502
Gain on divestiture	—			(1,284		)	—			—
Goodwill and tradename impairment	—			—			—			229,461
Total operating expenses	68,136			66,548			61,694			291,695
Operating income (loss)	72,487			70,924			77,541			(153,449		)
Net interest expense	25,940			27,070			26,327			25,745
Other expense (income), net	87			335			218			(164		)
Income (loss) before income taxes	46,460			43,519			50,996			(179,030		)
Provision (benefit) for income taxes	11,994			12,678			12,829			(39,756		)
Net income (loss)	$	34,466		$	30,841		$	38,167		$	(139,274	)

Earnings (loss) per share:
Basic	$	0.65		$	0.59		$	0.74		$	(2.68	)
Diluted	$	0.65		$	0.59		$	0.73		$	(2.68	)

Weighted average shares outstanding:
Basic	52,640			51,841			51,881			51,912
Diluted	52,942			52,153			52,202			51,912

Comprehensive (loss) income, net of tax:
Currency translation adjustments	(2,974		)	(2,145		)	(2,020		)	659
Unrecognized net gain on pension plans	—			—			—			48
Total other comprehensive (loss) income	(2,974		)	(2,145		)	(2,020		)	707
Comprehensive income (loss)	$	31,492		$	28,696		$	36,147		$	(138,567	)

Year Ended March 31, 2018



	Quarterly Period Ended
(In thousands, except for per share data)	June 30, 2017			September 30, 2017			December 31, 2017			March 31, 2018
Total revenues	$	256,573		$	258,026		$	270,615		$	255,965
Cost of sales	113,097			113,928			122,941			114,708
Gross profit	143,476			144,098			147,674			141,257

Operating expenses
Advertising and promotion	36,944			39,188			35,835			35,319
General and administrative	20,410			21,999			20,820			22,164
Depreciation and amortization	7,167			7,186			7,129			6,946
Tradename impairment	—			—			—			99,924
Total operating expenses	64,521			68,373			63,784			164,353
Operating income (loss)	78,955			75,725			83,890			(23,096		)
Net interest expense	26,341			26,836			25,864			26,838
Loss on extinguishment of debt	—			—			—			2,901
Other (income) expense, net	(74		)	(432		)	387			(273		)
Income (loss) before income taxes	52,688			49,321			57,639			(52,562		)
Provision (benefit) for income taxes	18,929			18,616			(257,154		)	(12,875		)
Net income (loss)	$	33,759		$	30,705		$	314,793		$	(39,687	)

Earnings (loss) per share:
Basic	$	0.64		$	0.58		$	5.93		$	(0.75	)
Diluted	$	0.63		$	0.57		$	5.88		$	(0.75	)

Weighted average shares outstanding:
Basic	53,038			53,098			53,129			53,131
Diluted	53,509			53,539			53,543			53,131

Comprehensive income, net of tax:
Currency translation adjustments	1,119			2,716			4,492			(2,625		)
Unrecognized net loss on pension plans	1			—			—			1,334
Total other comprehensive (loss) income	1,120			2,716			4,492			(1,291		)
Comprehensive (loss) income	$	34,879		$	33,421		$	319,285		$	(40,978	)

Subsequent Events	12 Months Ended
Subsequent Events	Mar. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Share Repurchase Program In May, 2019, the Company’s Board of Directors authorized the repurchase of up to $50.0 million of the Company’s issued and outstanding common stock. Under the authorization, the Company may purchase common stock through May, 2020 utilizing one or more open market transactions, transactions structured through investment banking institutions, in privately-negotiated transactions or otherwise, by direct purchases of common stock or a combination of the foregoing in compliance with the applicable rules and regulations of the Securities and Exchange Commission. The timing of the purchases and the amount of stock repurchased is subject to the Company's discretion and will depend on market and business conditions, applicable legal and credit requirements and other corporate considerations including the Company’s historical strategy of pursuing accretive acquisitions and deleveraging. Share Based Compensation On May 6, 2019, the Compensation and Talent Management Committee of our Board of Directors granted 98,645 performance units, 89,284 RSUs and stock options to acquire 281,486 shares of our common stock to certain executive officers and employees under the Plan. Performance units are earned based on achievement of the performance objectives set by the Compensation and Talent Management Committee and, if earned, vest in their entirety on the three-year anniversary of the date of grant. RSUs vest either 33.3% per year over three years or in their entirety on the three-year anniversary of the date of grant. Upon vesting, both performance units and RSUs will be settled in shares of our common stock. The stock options will vest 33.3% per year over three years and are exercisable for up to ten years from the date of grant. These stock options were granted at an exercise price of $30.56 per share, which is equal to the closing price for our common stock on the date of the grant. Except in cases of death, disability or retirement, termination of employment prior to vesting will result in forfeiture of the unvested performance units, RSUs and the stock options. Vested stock options will remain exercisable by the employee after termination, subject to the terms of the Plan. Logistics Provider Agreement On May 13, 2019, we entered into a Master Logistics Services Agreement with GEODIS Logistics LLC (“GEODIS”), pursuant to which GEODIS will serve as a new third party logistics provider. The agreement will have an initial term of five years with an option to renew for an additional five year term. Under the Master Logistics Services Agreement, we have authorized GEODIS to lease a facility under a five year term.

Schedule II Valuation and Qualifying Accounts

12 Months Ended

Mar. 31, 2019

SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]

Schedule II Valuation and Qualifying Accounts

VALUATION AND QUALIFYING ACCOUNTS



(In thousands)	Balance at Beginning of Year			Amounts Charged to Expense			Deductions			Other				Balance at End of Year
Year Ended March 31, 2019
Reserves for sales returns and allowance	$	8,813		$	56,276		$	(56,116	)	$	—			$	8,973
Reserves for trade promotions	13,062		^(a)	90,844			(88,415		)	—				15,491
Reserves for consumer coupon redemptions	2,645			5,199			(6,669		)	—				1,175
Allowance for doubtful accounts	1,203			203			(147		)	—				1,259
Deferred tax valuation allowance	609			2,627		^(b)	—			—				3,236

Year Ended March 31, 2018
Reserves for sales returns and allowance	9,429			62,953			(63,569		)	—				8,813
Reserves for trade promotions	15,193			78,669			(82,427		)	—				11,435
Reserves for consumer coupon redemptions	4,614			7,283			(9,252		)	—				2,645
Allowance for doubtful accounts	1,352			187			(336		)	—				1,203
Deferred tax valuation allowance	3,437			—			—			(2,828		)	^(c)	609

Year Ended March 31, 2017
Reserves for sales returns and allowance	8,823			41,173			(41,417		)	850			^(d)	9,429
Reserves for trade promotions	12,641			69,475			(69,713		)	2,790			^(d)	15,193
Reserves for consumer coupon redemptions	4,323			7,616			(7,745		)	420			^(d)	4,614
Allowance for doubtful accounts	815			177			360			—				1,352
Deferred tax valuation allowance	—			—			—			3,437			^(d)	3,437

(a) Reflects opening balance sheet adjustment related to the adoption of new revenue recognition standard.

(b) Relates to the unutilized foreign tax credit carryovers.

(d) Reflects the applicable amounts acquired from the purchase of Fleet on January 26, 2017.

Business and Basis of Presentation (Policies)

12 Months Ended

Mar. 31, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

Use of Estimates

Cash and Cash Equivalents

Accounts Receivable

Inventories

Property, Plant and Equipment

Property, plant and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:



	Years
Building	15 - 40
Machinery	3 - 15
Computer equipment and software	3 - 5
Furniture and fixtures	7 - 10
Leasehold improvements	*

*Leasehold improvements are amortized over the lesser of the lease term or the estimated useful life of the related assets.

Goodwill

Intangible Assets

Debt Origination Costs

Revenue Recognition

Cost of Sales

Revenue Recognition

Nature of Goods and Services

See Note 19 for disaggregated revenue information.

Satisfaction of Performance Obligations

Variable Consideration

Provisions for certain rebates, customer promotional programs, product returns, and discounts to customers are accounted for as variable consideration and recorded as a reduction in sales.

Practical Expedients

We expense incremental direct costs of obtaining a contract (broker commissions) when the related sale takes place.

We account for shipping and handling costs as fulfillment activities and therefore recognize them upon shipment of goods.

Stock-based Compensation

Pension Expense

Income Taxes

We are subject to taxation in the United States and various state and foreign jurisdictions.

We classify penalties and interest related to unrecognized tax benefits as income tax expense in the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss).

(Loss) Earnings Per Share

Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements

Recently Adopted Accounting Pronouncements

The effects of this recently adopted accounting pronouncement to our Consolidated Balance Sheet as of April 1, 2018 are as follows:



(In thousands)	Balance March 31, 2018		New Revenue Standard Adjustment			April 1, 2018
Accounts receivable, net	$	140,881	$	5,438		$	146,319
Inventories	118,547		(1,768		)	116,779
Other accrued liabilities	52,101		1,926			54,027
Deferred income tax liabilities	442,518		401			442,919
Retained earnings	736,277		1,343			737,620

Recently Issued Accounting Pronouncements

Business and Basis of Presentation (Tables)

12 Months Ended

Mar. 31, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Property, Plant and Equipment

Property, plant and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:



	Years
Building	15 - 40
Machinery	3 - 15
Computer equipment and software	3 - 5
Furniture and fixtures	7 - 10
Leasehold improvements	*

*Leasehold improvements are amortized over the lesser of the lease term or the estimated useful life of the related assets.

Property, plant and equipment, net consist of the following:



	March 31,
(In thousands)	2019			2018
Components of Property, Plant and Equipment
Land	$	550		$	550
Building	13,960			13,746
Machinery	42,472			38,599
Computer equipment	20,716			18,116
Furniture and fixtures	3,200			2,924
Leasehold improvements	9,090			8,804
	89,988			82,739
Accumulated depreciation	(38,812		)	(30,187		)
Property, plant and equipment, net	$	51,176		$	52,552

Computation of Basic and Diluted Earnings Per Share

The following table sets forth the computation of basic and diluted earnings per share:



	Year Ended March 31,
(In thousands, except per share data)	2019			2018		2017
Numerator
Net (loss) income	$	(35,800	)	$	339,570	$	69,395

Denominator
Denominator for basic (loss) earnings per share - weighted average shares outstanding	52,068			53,099		52,976
Dilutive effect of unvested restricted stock units and options issued to employees and directors	—			427		386
Denominator for diluted (loss) earnings per share	52,068			53,526		53,362

(Loss) earnings per Common Share:
Basic net (loss) earnings per share	$	(0.69	)	$	6.40	$	1.31

Diluted net (loss) earnings per share	$	(0.69	)	$	6.34	$	1.30

Impact of Adopting ASC 606

The impact of adopting ASC 606 on our Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) is as follows:



	Year Ended March 31, 2019
(In thousands)	As Reported			Impact of Change			Without Adoption of ASC 606
Total revenues	$	975,777		$	(14,756	)	$	961,021
Cost of sales	$	420,201		$	(5,220	)	$	414,981
Total operating expenses	$	488,073		$	(319	)	$	487,754
Loss before income taxes	$	(38,055	)	$	(9,217	)	$	(47,272	)
(Benefit) for income taxes	$	(2,255	)	$	(2,662	)	$	(4,917	)
Net loss	$	(35,800	)	$	(6,555	)	$	(42,355	)

The effects of this recently adopted accounting pronouncement to our Consolidated Balance Sheet as of April 1, 2018 are as follows:



(In thousands)	Balance March 31, 2018		New Revenue Standard Adjustment			April 1, 2018
Accounts receivable, net	$	140,881	$	5,438		$	146,319
Inventories	118,547		(1,768		)	116,779
Other accrued liabilities	52,101		1,926			54,027
Deferred income tax liabilities	442,518		401			442,919
Retained earnings	736,277		1,343			737,620

Divestitures and Sale of License Rights (Tables)

12 Months Ended

Mar. 31, 2019

Discontinued Operations and Disposal Groups [Abstract]

Components of assets sold and pre-tax gain

The following table sets forth the components of the assets sold and the pre-tax gain recognized on the sale in July 2018:



(In thousands)	July 2, 2018
Components of assets sold:
Inventory	$	6,644
Property, plant and equipment, net	653
Goodwill	6,245
Intangible assets, net	49,315
Assets sold	62,857
Total purchase price received	65,912
	(3,055		)
Costs to sell	1,771
Pre-tax gain on divestiture	$	(1,284	)

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760

+ Details

Property, Plant and Equipment (Tables)

12 Months Ended

Mar. 31, 2019

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

Property, plant and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:



	Years
Building	15 - 40
Machinery	3 - 15
Computer equipment and software	3 - 5
Furniture and fixtures	7 - 10
Leasehold improvements	*

*Leasehold improvements are amortized over the lesser of the lease term or the estimated useful life of the related assets.

Property, plant and equipment, net consist of the following:



	March 31,
(In thousands)	2019			2018
Components of Property, Plant and Equipment
Land	$	550		$	550
Building	13,960			13,746
Machinery	42,472			38,599
Computer equipment	20,716			18,116
Furniture and fixtures	3,200			2,924
Leasehold improvements	9,090			8,804
	89,988			82,739
Accumulated depreciation	(38,812		)	(30,187		)
Property, plant and equipment, net	$	51,176		$	52,552

Goodwill (Tables)

12 Months Ended

Mar. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Summary of Changes in Goodwill

The following table summarizes the changes in the carrying value of goodwill by operating segment for each of 2017, 2018, and 2019:



(In thousands)	North American OTC Healthcare			International OTC Healthcare			Household Cleaning			Consolidated
Balance – March 31, 2017
Goodwill	$	706,623		$	32,554		$	71,405		$	810,582
Accumulated impairment losses	(130,170		)	—			(65,160		)	(195,330		)
Balance - March 31, 2017	576,453			32,554			6,245			615,252

2018 Adjustments ^(a)	4,481			—			—			4,481
Effects of foreign currency exchange rates	—			365			—			365

Balance – March 31, 2018
Goodwill	711,104			32,919			71,405			815,428
Accumulated impairment losses	(130,170		)	—			(65,160		)	(195,330		)
Balance - March 31, 2018	580,934			32,919			6,245			620,098

2019 Additions	—			—			—			—
2019 Reductions:	—			—			—			—
Goodwill ^(b)	—			—			(71,405		)	(71,405		)
Accumulated impairment loss ^(b)	—			—			65,160			65,160
Effects of foreign currency exchange rates	—			(1,729		)	—			(1,729		)
Impairment loss	(33,541		)	—			—			(33,541		)

Balance – March 31, 2019
Goodwill	711,104			31,190			—			742,294
Accumulated impairment losses	(163,711		)	—			—			(163,711		)
Balance - March 31, 2019	$	547,393		$	31,190		$	—		$	578,583

(a) Amount relates to a measurement period adjustment recorded during 2018, associated with our Fleet acquisition.

(b) As discussed in Note 3, on July 2, 2018, we sold our Household Cleaning segment. As a result, we decreased goodwill by $6.2 million, net of accumulated impairment charges.

Intangible Assets (Tables)

12 Months Ended

Mar. 31, 2019

Intangible Assets, Net (Excluding Goodwill) [Abstract]

Reconciliation of the Activity Affecting Intangible Assets

A reconciliation of the activity affecting intangible assets, net for each of 2019 and 2018 is as follows:



	Year Ended March 31, 2019
(In thousands)	Indefinite- Lived Tradenames			Finite-Lived Tradenames and Customer Relationships			Totals
Gross Carrying Amounts
Balance – March 31, 2018	$	2,490,303		$	441,314		$	2,931,617
Reclassifications	(25,152		)	25,152			—
Reductions	(30,562		)	(34,889		)	(65,451		)
Tradename impairment	(154,967		)	(40,953		)	(195,920		)
Effects of foreign currency exchange rates	(6,431		)	(341		)	(6,772		)
Balance – March 31, 2019	$	2,273,191		$	390,283		$	2,663,474

Accumulated Amortization
Balance – March 31, 2018	$	—		$	150,701		$	150,701
Additions	—			21,767			21,767
Reductions	—			(16,136		)	(16,136		)
Effects of foreign currency exchange rates	—			(68		)	(68		)
Balance – March 31, 2019	$	—		$	156,264		$	156,264

Intangible assets, net – March 31, 2019	$	2,273,191		$	234,019		$	2,507,210

Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	2,195,617		$	228,743		$	2,424,360
International OTC Healthcare	77,574			5,276			82,850
Intangible assets, net – March 31, 2019	$	2,273,191		$	234,019		$	2,507,210



	Year Ended March 31, 2018
(In thousands)	Indefinite- Lived Tradenames			Finite-Lived Tradenames and Customer Relationships			Totals
Gross Carrying Amounts
Balance – March 31, 2017	$	2,589,155		$	441,801		$	3,030,956
Tradename impairment	(99,300		)	(624		)	(99,924		)
Effects of foreign currency exchange rates	448			137			585
Balance – March 31, 2018	$	2,490,303		$	441,314		$	2,931,617

Accumulated Amortization
Balance – March 31, 2017	$	—		$	127,343		$	127,343
Additions	—			23,349			23,349
Effects of foreign currency exchange rates	—			9			9
Balance – March 31, 2018	$	—		$	150,701		$	150,701

Intangible assets, net – March 31, 2018	$	2,490,303		$	290,613		$	2,780,916

Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	2,375,736		$	265,356		$	2,641,092
International OTC Healthcare	84,006			6,068			90,074
Household Cleaning	30,561			19,189			49,750
Intangible assets, net – March 31, 2018	$	2,490,303		$	290,613		$	2,780,916

Schedule of Expected Amortization Expense

At March 31, 2019, finite-lived intangible assets are expected to be amortized over their estimated useful life, which ranges from a period of 10 to 30 years, and the estimated amortization expense for each of the five succeeding years and periods thereafter is as follows (in thousands):



(In thousands)
Year Ending March 31,	Amount
2020	19,642
2021	19,646
2022	19,644
2023	19,644
2024	19,614
Thereafter	135,829
	$	234,019

Long-Term Debt (Tables)

12 Months Ended

Mar. 31, 2019

Debt Disclosure [Abstract]

Schedule of Long-term Debt

Long-term debt consists of the following, as of the dates indicated:



(In thousands, except percentages)	March 31, 2019			March 31, 2018
2016 Senior Notes bearing interest at 6.375%, with interest payable on March 1 and September 1 of each year. The 2016 Senior Notes mature on March 1, 2024.	$	600,000		$	600,000
2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year. The 2013 Senior Notes mature on December 15, 2021.	400,000			400,000
2012 Term B-5 Loans bearing interest at the Borrower's option at either LIBOR plus a margin of 2.00%, with a LIBOR floor of 0.00%, or an alternate base rate plus a margin of 1.00% with a floor of 1.00% due on January 26, 2024.	738,000			938,000
2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on January 26, 2022.	75,000			75,000
Long-term debt	1,813,000			2,013,000
Less: unamortized debt costs	(14,402		)	(20,048		)
Long-term debt, net	$	1,798,598		$	1,992,952

Schedule of Future Principal Payments



(In thousands)
Year Ending March 31,	Amount
2020	$	—
2021	—
2022	475,000
2023	—
2024	1,338,000
Thereafter	—
	$	1,813,000

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

Share-Based Compensation (Tables)

12 Months Ended

Mar. 31, 2019

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Summary of Restricted Shares

A summary of the Company’s RSUs granted under the Plan is presented below:



RSUs	Shares (in thousands)		Weighted-Average Grant-Date Fair Value
Vested and nonvested at March 31, 2016	467.8		$	35.22

Granted	68.4		55.44
Vested and issued	(94.7	)	28.51
Forfeited	(91.4	)	41.71
Vested and nonvested at March 31, 2017	350.1		39.29
Vested at March 31, 2017	63.4		20.12

Granted	105.8		55.61
Vested and issued	(53.3	)	34.30
Forfeited	(9.1	)	48.76
Vested and nonvested at March 31, 2018	393.5		44.13
Vested at March 31, 2018	90.5		29.88

Granted	226.4		30.09
Vested and issued	(175.8	)	43.05
Forfeited	(31.1	)	48.32
Vested and nonvested at March 31, 2019	413.0		36.58
Vested at March 31, 2019	113.2		31.05

Stock Options, Valuation Assumptions

The weighted-average grant-date fair values of the options granted during 2019, 2018, and 2017 were $10.22, $21.20, and $21.75, respectively.



	Year Ended March 31,
	2019		2018		2017
Expected volatility	29.6	%	35.2	%	37.8	%
Expected dividends	—		—		—
Expected term in years	6.0		6.0		6.0
Risk-free rate	2.9	%	2.2	%	1.7	%

Stock Option Activity

A summary of option activity under the Plan is as follows:



Options	Shares (in thousands)		Weighted-Average Exercise Price		Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value (in thousands)

Outstanding at March 31, 2016	727.7		$	30.70

Granted	264.3		55.86
Exercised	(126.8	)	31.75
Forfeited or expired	(92.9	)	42.66
Outstanding at March 31, 2017	772.3		37.70

Granted	182.8		56.11
Exercised	(55.7	)	29.08
Forfeited or expired	(26.2	)	48.19
Outstanding at March 31, 2018	873.2		41.79

Granted	294.5		29.46
Exercised	(97.7	)	30.02
Forfeited or expired	(125.4	)	47.16
Outstanding at March 31, 2019	944.6		38.45		7.0	$	2,048
Exercisable at March 31, 2019	499.4		37.87		5.5	$	1,921

Employee Retirement Plans (Tables)

12 Months Ended

Mar. 31, 2019

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Benefit Obligation and Plan Assets

The following table summarizes the changes in the U.S. pension plan obligations and plan assets and includes a statement of the plans' funded status as of March 31, 2019 and 2018:



	March 31,
(In thousands)	2019			2018
Change in benefit obligation:
Projected benefit obligation at beginning of period	$	61,882		$	61,714
Interest cost	2,380			2,529
Actuarial (gain) loss	(744		)	800
Benefits paid	(3,184		)	(3,161		)
Projected benefit obligations at end of year	$	60,334		$	61,882

Change in plan assets:
Fair value of plan assets at beginning of period	$	50,508		$	47,772
Actual return on plan assets	2,416			5,505
Employer contribution	1,375			392
Benefits paid	(3,184		)	(3,161		)
Fair value of plan assets at end of year	$	51,115		$	50,508

Funded status at end of year	$	(9,219	)	$	(11,374	)

Schedule of Amounts Recognized in Balance Sheet

Amounts recognized in the balance sheet at the end of the period consist of the following:



	March 31,
(In thousands)	2019		2018
Current liability	$	361	461
Long-term liability	8,858		10,913
Total	$	9,219	$	11,374

Schedule of Primary Components of Net Periodic Benefits

The primary components of Net Periodic Benefits consist of the following:



	Year Ended March 31,
(In thousands)	2019			2018			2017
Interest cost	$	2,380		$	2,529		$	456
Expected return on assets	(3,070		)	(2,901		)	(462		)
Net periodic benefit cost (income)	$	(690	)	$	(372	)	$	(6	)

Schedule of Expected to be Contributed



(In thousands)	Pension Benefits
Employer contributions:
2020 (expectation) to participant benefits	$	1,361

Expected benefit payments year ending March 31,
2020	$	3,371
2021	3,472
2022	3,592
2023	3,678
2024	3,743
2025-2029	18,771

Schedule of Allocation of Plan Assets

The asset allocation for the Company's funded retirement plan as of March 31, 2019 and 2018, and the target allocation by asset category are as follows:



	Percentage of Plan Assets
Asset Category	Target Allocation		March 31, 2019		March 31, 2018
Domestic large cap equities	18	%	18	%	21	%
Domestic small/mid cap equities	5		5		6
International equities	15		15		18
Fixed income and cash	62		62		55
Total	100	%	100	%	100	%

Schedule of Amounts in Accumulated Other Comprehensive Income (Loss)



(In thousands)
Balances in accumulated other comprehensive loss as of March 31, 2017:
Unrecognized actuarial loss	$	399
Unrecognized prior service credit	—

Balances in accumulated other comprehensive loss as of March 31, 2018:
Unrecognized actuarial (gain)	$	(1,407	)
Unrecognized prior service credit	—

Balances in accumulated other comprehensive (income) as of March 31, 2019:
Unrecognized actuarial (gain)	$	(1,469	)
Unrecognized prior service credit	—

Amounts expected to be reclassified from accumulated other comprehensive income (loss) during 2020:
Unrecognized actuarial (loss)	$	—
Unrecognized prior service credit	—

Schedule of Assumptions Used

Assumptions used in determining the actuarial present value of the benefit obligation as of March 31, 2019 and 2018 were as follows:



	March 31,
	2019	2018
Key assumptions:
Discount rate	3.80% to 3.99%	3.93% to 4.07%
Expected return on plan assets, net of administrative fees	5.75%	6.25%
Rate of compensation increase	—	—

Income Taxes (Tables)

12 Months Ended

Mar. 31, 2019

Income Tax Disclosure [Abstract]

Income from Continuing Operations Before Income Taxes, Domestic and Foreign

Income (loss) before income taxes consists of the following:



	Year Ended March 31,
(In thousands)	2019			2018		2017
United States	$	(52,313	)	$	84,435	$	93,582
Foreign	14,258			22,651		17,268
	$	(38,055	)	$	107,086	$	110,850

Components of Provision for Income Taxes

The (benefit) provision for income taxes consists of the following:



	Year Ended March 31,
(In thousands)	2019			2018			2017
Current
Federal	$	27,629		$	31,327		$	40,183
State	3,156			2,686			2,808
Foreign	7,193			5,588			4,242
Deferred
Federal	(35,760		)	(270,796		)	(5,421		)
State	(4,101		)	(1,240		)	(163		)
Foreign	(372		)	(49		)	(194		)
Total (benefit) provision for income taxes	$	(2,255	)	$	(232,484	)	$	41,455

Components of Deferred Tax Balances

The principal components of our deferred tax balances are as follows:



	March 31,
(In thousands)	2019			2018
Deferred Tax Assets
Allowance for doubtful accounts and sales returns	$	3,285		$	2,806
Inventory capitalization	1,245			1,176
Inventory reserves	1,267			540
Net operating loss carryforwards	226			609
State income taxes	9,003			10,154
Accrued liabilities	1,785			2,210
Accrued compensation	4,416			4,992
Stock compensation	4,206			5,038
Foreign tax credit	3,236			—
Interest	154			—
Other	7,691			4,975
Total deferred tax assets	$	36,514		$	32,500

Deferred Tax Liabilities
Property, plant and equipment	$	(6,002	)	$	(6,032	)
Intangible assets	(425,134		)	(467,388		)
Adoption of revenue recognition standard	(721		)	—
Total deferred tax liabilities	$	(431,857	)	$	(473,420	)

Net deferred tax liability before valuation allowance	$	(395,343	)	$	(440,920	)
Valuation allowance	(3,236		)	(609		)
Net deferred tax liability	$	(398,579	)	$	(441,529	)

Reconciliation of Effective Tax Rate

A reconciliation of the effective tax rate compared to the statutory U.S. Federal tax rate is as follows:



	Year Ended March 31,
	2019					2018					2017
(In thousands)				%					%					%
Income tax (benefit) provision at statutory rate	$	(7,992	)	21.0		$	37,480		35.0		$	38,798		35.0
Foreign tax provision (benefit)	2,866			(7.5	)	(2,084		)	(1.9	)	(2,322		)	(2.1	)
State income taxes, net of federal income tax benefit	(1,710		)	4.5		1,414			1.3		1,820			1.7
Impact of tax legislation	—			—		(268,244		)	(250.5	)	—			—
Goodwill impairment	5,616			(14.8	)	—			—		3,208			2.9
R&D	(629		)	1.7		—			—		—			—
Compensation limitations	296			(0.8	)	—			—		—			—
Valuation allowance	2,627			(6.9	)	(2,828		)	(2.6	)	—			—
Gain on sale	1,312			(3.4	)	—			—		—			—
Nondeductible transaction costs	—			—		—			—		686			0.6
Nondeductible compensation	—			—		—			—		342			0.3
Other	(4,641		)	12.1		1,778			1.6		(1,077		)	(1.0	)
Total (benefit) provision for income taxes	$	(2,255	)	5.9		$	(232,484	)	(217.1	)	$	41,455		37.4

Uncertain Tax Liability Activity

Uncertain tax liability activity is as follows:



	2019			2018			2017
(In thousands)
Balance – beginning of year	$	10,827		$	3,651		$	4,084
Additions based on tax positions related to the current year	585			7,286			583
Reductions based on lapse of statute of limitations	(650		)	(110		)	(1,016		)
Payments and other movements	(888		)	—			—
Balance – end of year	$	9,874		$	10,827		$	3,651

Commitments and Contingencies (Tables)

12 Months Ended

Mar. 31, 2019

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases

The following summarizes future minimum lease payments for our operating leases as of March 31, 2019 ^(a):



(In thousands)	Facilities		Equipment		Total
Year Ending March 31,
2020	$	2,828	$	314	$	3,142
2021	2,633		248		2,881
2022	2,265		213		2,478
2023	1,684		105		1,789
2024	1,705		—		1,705
Thereafter	6,780		—		6,780
	$	17,895	$	880	$	18,775

(a) Minimum lease payments have not been reduced by minimum sublease rentals of $0.5 million due in the future under non- cancellable subleases.

The following schedule shows the composition of total minimum lease payments that have been reduced by minimum sublease rentals:



	Year ending March 31,
(In thousands)	2019			2018
Minimum lease payments	$	18,775		$	20,987
Less: Sublease rentals	(509		)	(1,018		)
	$	18,266		$	19,969

Unrecorded Unconditional Purchase Obligations

The following table shows the minimum amounts that we are committed to pay under these agreements:



(In thousands)
Year Ending March 31,	Amount
2020	$	9,802
2021	9,719
2022	9,497
2023	1,650
2024	—
Thereafter	—
	$	30,668

Business Segments (Tables)

12 Months Ended

Mar. 31, 2019

Segment Reporting [Abstract]

Information about our Operating and Reportable Segments

The tables below summarize information about our operating and reportable segments.



	Year Ended March 31, 2019
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Total segment revenues*	$	862,446	$	93,520	$	19,811	$	975,777
Cost of sales	364,533		39,080		16,588		420,201
Gross profit	497,913		54,440		3,223		555,576
Advertising and promotion	126,374		16,286		430		143,090
Contribution margin	$	371,539	$	38,154	$	2,793	412,486
Other operating expenses**							344,983
Operating income							67,503
Other expense							105,558
Loss before income taxes							(38,055		)
Benefit for income taxes							(2,255		)
Net loss							$	(35,800	)

*Intersegment revenues of $7.4 million were eliminated from the North American OTC Healthcare segment.

**Other operating expenses for the year ended March 31, 2019 includes a tradename impairment charge of $195.9 million and a goodwill impairment charge of $33.5 million .



	Year Ended March 31, 2018
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Total segment revenues*	$	868,874	$	91,658	$	80,647	$	1,041,179
Cost of sales	357,298		40,244		67,132		464,674
Gross profit	511,576		51,414		13,515		576,505
Advertising and promotion	129,058		16,267		1,961		147,286
Contribution margin	$	382,518	$	35,147	$	11,554	429,219
Other operating expenses**							213,745
Operating income							215,474
Other expense							108,388
Income before income taxes							107,086
Provision for income taxes							(232,484		)
Net income							$	339,570

* Intersegment revenues of $7.7 million were eliminated from the North American OTC Healthcare segment.

**Other operating expenses for the year ended March 31, 2018 includes a tradename impairment charge of $99.9 million.



	Year Ended March 31, 2017
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Total segment revenues*	$	720,824	$	73,304	$	87,932	$	882,060
Cost of sales	282,750		30,789		68,235		381,774
Gross profit	438,074		42,515		19,697		500,286
Advertising and promotion	112,465		13,434		2,460		128,359
Contribution margin	$	325,609	$	29,081	$	17,237	371,927
Other operating expenses**							166,284
Operating income							205,643
Other expense							94,793
Income before income taxes							110,850
Provision for income taxes							41,455
Net income							$	69,395

*Intersegment revenues of $4.2 million were eliminated from the North America OTC Healthcare segment.

Information about our Revenues from Similar Product Groups

The tables below summarize information about our segment revenues from similar product groups.



	Year Ended March 31, 2019
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	113,563	$	615	$	—	$	114,178
Cough & Cold	83,168		19,955		—		103,123
Women's Health	244,927		13,552		—		258,479
Gastrointestinal	125,416		35,046		—		160,462
Eye & Ear Care	101,128		11,709		—		112,837
Dermatologicals	95,801		2,171		—		97,972
Oral Care	92,964		10,468		—		103,432
Other OTC	5,479		4		—		5,483
Household Cleaning	—		—		19,811		19,811
Total segment revenues	$	862,446	$	93,520	$	19,811	$	975,777



	Year Ended March 31, 2018
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	118,610	$	807	$	—	$	119,417
Cough & Cold	93,537		18,310		—		111,847
Women's Health	247,244		12,140		—		259,384
Gastrointestinal	117,627		34,609		—		152,236
Eye & Ear Care	92,308		11,744		—		104,052
Dermatologicals	94,775		2,113		—		96,888
Oral Care	99,072		11,930		—		111,002
Other OTC	5,701		5		—		5,706
Household Cleaning	—		—		80,647		80,647
Total segment revenues	$	868,874	$	91,658	$	80,647	$	1,041,179



	Year Ended March 31, 2017
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	120,253	$	1,922	$	—	$	122,175
Cough & Cold	90,795		17,990		—		108,785
Women's Health	147,071		3,811		—		150,882
Gastrointestinal	76,500		24,812		—		101,312
Eye & Ear Care	97,618		12,075		—		109,693
Dermatologicals	85,194		2,159		—		87,353
Oral Care	97,586		10,513		—		108,099
Other OTC	5,807		22		—		5,829
Household Cleaning	—		—		87,932		87,932
Total segment revenues	$	720,824	$	73,304	$	87,932	$	882,060

Segment Revenue by Geographic Area

Our total segment revenues by geographic area are as follows:



	Year Ended March 31,
	2019		2018		2017
United States	$	837,049	$	903,511	$	769,732
Rest of world	138,728		137,668		112,328
Total	$	975,777	$	1,041,179	$	882,060

Allocation of Long-Term Assets to Segments

Our consolidated goodwill and intangible assets have been allocated to the reportable segments as follows:



March 31, 2019 (In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Goodwill	$	547,393	$	31,190	$	—	$	578,583

Intangible assets
Indefinite-lived	2,195,617		77,574		—		2,273,191
Finite-lived	228,743		5,276		—		234,019
Intangible assets, net	$	2,424,360	82,850		—		2,507,210
Total	$	2,971,753	$	114,040	$	—	$	3,085,793



March 31, 2018 (In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Goodwill	$	580,934	$	32,919	$	6,245	$	620,098

Intangible assets
Indefinite-lived	2,375,736		84,006		30,561		2,490,303
Finite-lived	265,356		6,068		19,189		290,613
Intangible assets, net	2,641,092		90,074		49,750		2,780,916
Total	$	3,222,026	$	122,993	$	55,995	$	3,401,014

Goodwill and Intangible Assets by Geographic Areas

Our goodwill and intangible assets by geographic area are as follows:



	Year Ended March 31,
	2019		2018
United States	$	2,971,753	$	3,278,021
Rest of world	114,040		122,993
Total	$	3,085,793	$	3,401,014

Unaudited Quarterly Financial Information (Tables)

12 Months Ended

Mar. 31, 2019

Quarterly Financial Information Disclosure [Abstract]

Schedule of Quarterly Financial Information

Unaudited quarterly financial information for 2019 and 2018 is as follows:

Year Ended March 31, 2019



	Quarterly Period Ended
(In thousands, except for per share data)	June 30, 2018			September 30, 2018			December 31, 2018			March 31, 2019
Total revenues	$	253,980		$	239,357		$	241,414		$	241,026
Cost of sales	113,357			101,885			102,179			102,780
Gross profit	140,623			137,472			139,235			138,246

Operating expenses
Advertising and promotion	37,111			37,042			34,504			34,433
General and administrative	23,941			24,034			20,485			21,299
Depreciation and amortization	7,084			6,756			6,705			6,502
Gain on divestiture	—			(1,284		)	—			—
Goodwill and tradename impairment	—			—			—			229,461
Total operating expenses	68,136			66,548			61,694			291,695
Operating income (loss)	72,487			70,924			77,541			(153,449		)
Net interest expense	25,940			27,070			26,327			25,745
Other expense (income), net	87			335			218			(164		)
Income (loss) before income taxes	46,460			43,519			50,996			(179,030		)
Provision (benefit) for income taxes	11,994			12,678			12,829			(39,756		)
Net income (loss)	$	34,466		$	30,841		$	38,167		$	(139,274	)

Earnings (loss) per share:
Basic	$	0.65		$	0.59		$	0.74		$	(2.68	)
Diluted	$	0.65		$	0.59		$	0.73		$	(2.68	)

Weighted average shares outstanding:
Basic	52,640			51,841			51,881			51,912
Diluted	52,942			52,153			52,202			51,912

Comprehensive (loss) income, net of tax:
Currency translation adjustments	(2,974		)	(2,145		)	(2,020		)	659
Unrecognized net gain on pension plans	—			—			—			48
Total other comprehensive (loss) income	(2,974		)	(2,145		)	(2,020		)	707
Comprehensive income (loss)	$	31,492		$	28,696		$	36,147		$	(138,567	)

Year Ended March 31, 2018



	Quarterly Period Ended
(In thousands, except for per share data)	June 30, 2017			September 30, 2017			December 31, 2017			March 31, 2018
Total revenues	$	256,573		$	258,026		$	270,615		$	255,965
Cost of sales	113,097			113,928			122,941			114,708
Gross profit	143,476			144,098			147,674			141,257

Operating expenses
Advertising and promotion	36,944			39,188			35,835			35,319
General and administrative	20,410			21,999			20,820			22,164
Depreciation and amortization	7,167			7,186			7,129			6,946
Tradename impairment	—			—			—			99,924
Total operating expenses	64,521			68,373			63,784			164,353
Operating income (loss)	78,955			75,725			83,890			(23,096		)
Net interest expense	26,341			26,836			25,864			26,838
Loss on extinguishment of debt	—			—			—			2,901
Other (income) expense, net	(74		)	(432		)	387			(273		)
Income (loss) before income taxes	52,688			49,321			57,639			(52,562		)
Provision (benefit) for income taxes	18,929			18,616			(257,154		)	(12,875		)
Net income (loss)	$	33,759		$	30,705		$	314,793		$	(39,687	)

Earnings (loss) per share:
Basic	$	0.64		$	0.58		$	5.93		$	(0.75	)
Diluted	$	0.63		$	0.57		$	5.88		$	(0.75	)

Weighted average shares outstanding:
Basic	53,038			53,098			53,129			53,131
Diluted	53,509			53,539			53,543			53,131

Comprehensive income, net of tax:
Currency translation adjustments	1,119			2,716			4,492			(2,625		)
Unrecognized net loss on pension plans	1			—			—			1,334
Total other comprehensive (loss) income	1,120			2,716			4,492			(1,291		)
Comprehensive (loss) income	$	34,879		$	33,421		$	319,285		$	(40,978	)

Business and Basis of Presentation (Reclassifications) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
General and administrative expense	$ (21,299)	$ (20,485)	$ (24,034)	$ (23,941)	$ (22,164)	$ (20,820)	$ (21,999)	$ (20,410)	$ (89,759)	$ (85,393)	$ (89,113)
Other (income) expense	$ 164	$ (218)	$ (335)	$ (87)	$ 273	$ (387)	$ 432	$ 74	(476)	$ 392	$ (30)
Accounting Standards Update 2017-07
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Other (income) expense									$ 1,000

Business and Basis of Presentation (Cash and Cash Equivalents) (Details) $ in Millions	12 Months Ended
	Mar. 31, 2019 USD ($)
Cash and Cash Equivalents [Line Items]
Non-cash financing activities	$ 0.6
Sydney, Australia
Cash and Cash Equivalents [Line Items]
Percentage of deposits held in one location (as percent)	37.00%

Business and Basis of Presentation (Property, Plant and Equipment) (Details)	12 Months Ended
	Mar. 31, 2019
Building \| Minimum
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	15 years
Building \| Maximum
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	40 years
Machinery \| Minimum
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	3 years
Machinery \| Maximum
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	15 years
Computer equipment and software \| Minimum
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	3 years
Computer equipment and software \| Maximum
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	5 years
Furniture and fixtures \| Minimum
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	7 years
Furniture and fixtures \| Maximum
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	10 years

Business and Basis of Presentation (Revenue Recognition) (Details) $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Sep. 30, 2018 USD ($)	Jun. 30, 2018 USD ($)	Mar. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Sep. 30, 2017 USD ($)	Jun. 30, 2017 USD ($)	Mar. 31, 2019 USD ($) segment	Mar. 31, 2018 USD ($)	Mar. 31, 2017 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cost of sales \| $	$ 102,780	$ 102,179	$ 101,885	$ 113,357	$ 114,708	$ 122,941	$ 113,928	$ 113,097	$ 420,201	$ 464,674	$ 381,774
Number of operating segments \| segment									2

Business and Basis of Presentation (Income Taxes) (Details) $ in Millions	12 Months Ended
	Mar. 31, 2018 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net gain related to deferred tax liability	$ 267.0
Net gain related to the lower blended tax rate	3.2
Net gain	270.2
Repatriation charge	$ 1.9

Business and Basis of Presentation (Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Numerator
Net income	$ (139,274)	$ 38,167	$ 30,841	$ 34,466	$ (39,687)	$ 314,793	$ 30,705	$ 33,759	$ (35,800)	$ 339,570	$ 69,395
Denominator
Denominator for basic (loss) earnings per share - weighted average shares (in shares)	51,912	51,881	51,841	52,640	53,131	53,129	53,098	53,038	52,068	53,099	52,976
Dilutive effect of unvested restricted common stock and options issued to employees and directors (in shares)									0	427	386
Denominator for diluted (loss) earnings per share (in shares)	51,912	52,202	52,153	52,942	53,131	53,543	53,539	53,509	52,068	53,526	53,362
(Loss) earnings per Common Share:
Basic net (loss) earnings per share (in USD per share)	$ (2.68)	$ 0.74	$ 0.59	$ 0.65	$ (0.75)	$ 5.93	$ 0.58	$ 0.64	$ (0.69)	$ 6.40	$ 1.31
Diluted net (loss) earnings per share (in USD per share)	$ (2.68)	$ 0.73	$ 0.59	$ 0.65	$ (0.75)	$ 5.88	$ 0.57	$ 0.63	$ (0.69)	$ 6.34	$ 1.30
Antidilutive securities excluded from computation of earnings per share (in shares)									1,400	400	200

Business and Basis of Presentation (Impact of Adopting ASC 606) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017	Apr. 01, 2018
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenues									$ 975,777
Total operating expenses	$ 291,695	$ 61,694	$ 66,548	$ 68,136	$ 164,353	$ 63,784	$ 68,373	$ 64,521	488,073	$ 361,031	$ 294,643
Loss before income taxes	(179,030)	50,996	43,519	46,460	(52,562)	57,639	49,321	52,688	(38,055)	107,086	110,850
Provision (benefit) for income taxes	(39,756)	12,829	12,678	11,994	(12,875)	(257,154)	18,616	18,929	(2,255)	(232,484)	41,455
Net income	(139,274)	$ 38,167	$ 30,841	$ 34,466	(39,687)	$ 314,793	$ 30,705	$ 33,759	(35,800)	339,570	$ 69,395
Accounts receivable, net	148,787				140,881				148,787	140,881
Inventories	119,880				118,547				119,880	118,547
Other accrued liabilities	60,663				52,101				60,663	52,101
Deferred income tax liabilities	399,575				442,518				399,575	442,518
Retained earnings	$ 701,820				736,277				701,820	736,277
ASC 606
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Accounts receivable, net												$ 146,319
Inventories												116,779
Other accrued liabilities												54,027
Deferred income tax liabilities												442,919
Retained earnings												737,620
Impact of Change \| ASC 606
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenues									(14,756)
Cost of sales									(5,220)
Total operating expenses									(319)
Loss before income taxes									(9,217)
Provision (benefit) for income taxes									(2,662)
Net income									(6,555)
Accounts receivable, net												5,438
Inventories												(1,768)
Other accrued liabilities												1,926
Deferred income tax liabilities												401
Retained earnings												$ 1,343
Without Adoption of ASC 606
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenues									961,021
Cost of sales									414,981
Total operating expenses									487,754
Loss before income taxes									(47,272)
Provision (benefit) for income taxes									(4,917)
Net income									$ (42,355)
Without Adoption of ASC 606 \| ASC 606
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Accounts receivable, net					140,881					140,881
Inventories					118,547					118,547
Other accrued liabilities					52,101					52,101
Deferred income tax liabilities					442,518					442,518
Retained earnings					$ 736,277					$ 736,277

Acquisition (Details) - C.B. Fleet Company, Inc.	Jan. 26, 2017 USD ($)
Business Acquisition [Line Items]
Purchase price	$ 823,700,000
Term Loans
Business Acquisition [Line Items]
Debt instrument, face amount	$ 740,000,000

Divestitures and Sale of License Rights (Narrative) (Details) - USD ($) $ in Thousands		1 Months Ended				3 Months Ended								12 Months Ended
	Jul. 02, 2018	Dec. 31, 2016	Sep. 30, 2016	Aug. 31, 2016	Dec. 31, 2014	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017	Jul. 07, 2016
Divestitures and Sale of License Rights (Details)
(Gain) loss on divestitures						$ 0	$ 0	$ (1,284)	$ 0					$ (1,284)	$ 0	$ 51,820
Total revenues						$ 241,026	$ 241,414	$ 239,357	$ 253,980	$ 255,965	$ 270,615	$ 258,026	$ 256,573	975,777	1,041,179	882,060
Comet Brand
Divestitures and Sale of License Rights (Details)
Proceeds from early buyout					$ 10,000
Proceeds from sale of license rights				$ 11,000
Gain on sale of asset				1,200
Indefinite-lived intangibles, reductions				$ 9,000
North American OTC Healthcare
Divestitures and Sale of License Rights (Details)
Total revenues														$ 862,446	$ 868,874	720,824
Disposal group, disposed of by sale, not discontinued operations \| Household Cleaning
Divestitures and Sale of License Rights (Details)
Total purchase price received	$ 65,912
Pre-tax gain on divestiture	$ 1,284
Disposal group, disposed of by sale, not discontinued operations \| Pediacare, New Skin and Fiber Choice \| Cough and Cold, Dermatologicals, and Gastrointestinal products group \| North American OTC Healthcare
Divestitures and Sale of License Rights (Details)
Consideration, excluding costs of inventory																	$ 40,000
(Gain) loss on divestitures																$ 56,200
Disposal group, disposed of by sale, not discontinued operations \| Dermoplast \| Cough and Cold, Dermatologicals, and Gastrointestinal products group \| North American OTC Healthcare
Divestitures and Sale of License Rights (Details)
Deposit for agreement to purchase			$ 1,250
Disposal group, disposed of by sale, not discontinued operations \| E.P.T. and Dermoplast \| Cough and Cold, Dermatologicals, and Gastrointestinal products group \| North American OTC Healthcare
Divestitures and Sale of License Rights (Details)
Total purchase price received		$ 59,600
Pre-tax net gain on divestitures		$ 3,900
Royalty \| Comet Brand
Divestitures and Sale of License Rights (Details)
Total revenues					$ 1,000

Divestitures and Sale of License Rights (Components of Assets Sold and Pre-tax Gain) (Details) - Household Cleaning - Disposal group, disposed of by sale, not discontinued operations $ in Thousands	Jul. 02, 2018 USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Inventory	$ 6,644
Property, plant and equipment, net	653
Goodwill	6,245
Intangible assets, net	49,315
Assets sold	62,857
Total purchase price received	65,912
Gain on disposal	(3,055)
Costs to sell	1,771
Pre-tax gain on divestiture	$ 1,284

Accounts Receivable (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Mar. 31, 2018
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$ 161,752	$ 153,615
Less allowances for discounts, returns and uncollectible accounts	(12,965)	(12,734)
Accounts receivable, net	148,787	140,881
Trade accounts receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	161,047	152,832
Other receivables
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$ 705	$ 783

Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Mar. 31, 2018
Inventory Disclosure [Abstract]
Packaging and raw materials	$ 17,082	$ 13,112
Work in process	161	157
Finished goods	102,637	105,278
Inventories	119,880	118,547
Inventory valuation reserves related to obsolete and slow-moving inventory	$ 5,500	$ 4,200

Property, Plant and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Components of Property, Plant and Equipment
Property, plant and equipment, gross	$ 89,988	$ 82,739
Accumulated depreciation	(38,812)	(30,187)
Property, plant and equipment, net	51,176	52,552
Depreciation expense	10,000	10,100	$ 6,000
Land
Components of Property, Plant and Equipment
Property, plant and equipment, gross	550	550
Building
Components of Property, Plant and Equipment
Property, plant and equipment, gross	13,960	13,746
Machinery
Components of Property, Plant and Equipment
Property, plant and equipment, gross	42,472	38,599
Computer equipment
Components of Property, Plant and Equipment
Property, plant and equipment, gross	20,716	18,116
Furniture and fixtures
Components of Property, Plant and Equipment
Property, plant and equipment, gross	3,200	2,924
Leasehold improvements
Components of Property, Plant and Equipment
Property, plant and equipment, gross	$ 9,090	$ 8,804

Goodwill (Schedule of Changes) (Details) - USD ($)		12 Months Ended
Goodwill (Schedule of Changes) (Details) - USD ($)	Jul. 02, 2018	Mar. 31, 2019	Mar. 31, 2018
Goodwill [Roll Forward]
Goodwill, gross, beginning		$ 815,428,000	$ 810,582,000
Accumulated impairment loss, beginning		(195,330,000)	(195,330,000)
Goodwill, net, beginning		620,098,000	615,252,000
Adjustments			4,481,000
Additions		0
Goodwill, written off related to sale of business unit		71,405,000
Goodwill impairment, written off related to sale of business unit		65,160,000
Accumulated impairment loss		(33,541,000)	0
Effects of foreign currency exchange rates		(1,729,000)	365,000
Goodwill, gross, ending		742,294,000	815,428,000
Accumulated impairment loss, ending		(163,711,000)	(195,330,000)
Goodwill, net, ending		578,583,000	620,098,000
North American OTC Healthcare
Goodwill [Roll Forward]
Goodwill, gross, beginning		711,104,000	706,623,000
Accumulated impairment loss, beginning		(130,170,000)	(130,170,000)
Goodwill, net, beginning		580,934,000	576,453,000
Adjustments			4,481,000
Additions		0
Goodwill, written off related to sale of business unit		0
Goodwill impairment, written off related to sale of business unit		0
Accumulated impairment loss		(33,541,000)
Effects of foreign currency exchange rates		0	0
Goodwill, gross, ending		711,104,000	711,104,000
Accumulated impairment loss, ending		(163,711,000)	(130,170,000)
Goodwill, net, ending		547,393,000	580,934,000
International OTC Healthcare
Goodwill [Roll Forward]
Goodwill, gross, beginning		32,919,000	32,554,000
Accumulated impairment loss, beginning		0	0
Goodwill, net, beginning		32,919,000	32,554,000
Adjustments			0
Additions		0
Goodwill, written off related to sale of business unit		0
Goodwill impairment, written off related to sale of business unit		0
Accumulated impairment loss		0
Effects of foreign currency exchange rates		(1,729,000)	365,000
Goodwill, gross, ending		31,190,000	32,919,000
Accumulated impairment loss, ending		0	0
Goodwill, net, ending		31,190,000	32,919,000
Household Cleaning
Goodwill [Roll Forward]
Goodwill, gross, beginning		71,405,000	71,405,000
Accumulated impairment loss, beginning		(65,160,000)	(65,160,000)
Goodwill, net, beginning		6,245,000	6,245,000
Adjustments			0
Additions		0
Goodwill, written off related to sale of business unit	$ 6,200,000	71,405,000
Goodwill impairment, written off related to sale of business unit		65,160,000
Accumulated impairment loss		0
Effects of foreign currency exchange rates		0	0
Goodwill, gross, ending		0	71,405,000
Accumulated impairment loss, ending		0	(65,160,000)
Goodwill, net, ending		$ 0	$ 6,245,000

Intangible Assets (Reconciliation of Activity) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Indefinite- Lived Tradenames
Indefinite-lived intangibles, beginning	$ 2,490,303
Indefinite-lived intangibles, tradename impairment	(155,000)
Indefinite-lived intangibles, ending	2,273,191	$ 2,490,303
Gross Carrying Amounts
Finite-lived intangibles, tradename impairment		(600)
Accumulated Amortization
Finite-lived intangibles, accumulated amortization, beginning	150,701	127,343
Finite-lived intangibles, accumulated amortization, additions	21,767	23,349
Finite-lived intangible assets, accumulated amortization, reductions	(16,136)
Finite-lived intangibles, accumulated amortization, effects of foreign currency exchange rates	(68)	9
Finite-lived intangibles, accumulated amortization, ending	156,264	150,701
Gross Carrying Amounts
Intangible assets, gross, beginning	2,931,617	3,030,956
Reclassifications	0
Reductions	(65,451)
Impairment loss	195,920	99,924
Effects of foreign currency exchange rates	(6,772)	585
Intangible assets, gross, ending	2,663,474	2,931,617
Indefinite-lived intangible assets	2,490,303	2,490,303	$ 2,273,191	$ 2,490,303
Finite-lived intangible assets			234,019	290,613
Intangible assets, net (excluding goodwill)			2,507,210	2,780,916
North American OTC Healthcare
Indefinite- Lived Tradenames
Indefinite-lived intangibles, beginning	2,375,736
Indefinite-lived intangibles, ending	2,195,617	2,375,736
Gross Carrying Amounts
Indefinite-lived intangible assets	2,375,736	2,375,736	2,195,617	2,375,736
Finite-lived intangible assets			228,743	265,356
Intangible assets, net (excluding goodwill)			2,424,360	2,641,092
International OTC Healthcare
Indefinite- Lived Tradenames
Indefinite-lived intangibles, beginning	84,006
Indefinite-lived intangibles, ending	77,574	84,006
Gross Carrying Amounts
Indefinite-lived intangible assets	84,006	84,006	77,574	84,006
Finite-lived intangible assets			5,276	6,068
Intangible assets, net (excluding goodwill)			82,850	90,074
Household Cleaning
Indefinite- Lived Tradenames
Indefinite-lived intangibles, beginning	30,561
Indefinite-lived intangibles, ending	0	30,561
Gross Carrying Amounts
Indefinite-lived intangible assets	30,561	30,561	0	30,561
Finite-lived intangible assets			0	19,189
Intangible assets, net (excluding goodwill)			0	49,750
Finite-Lived Tradenames and Customer Relationships
Gross Carrying Amounts
Finite-lived intangibles, gross, beginning	441,314	441,801
Finite-lived intangibles, reductions	(34,889)
Finite-lived intangibles, tradename impairment	(40,953)	(624)
Finite-lived intangibles, effects of foreign currency exchange rates	(341)	137
Finite-lived intangibles, gross, ending	390,283	441,314
Accumulated Amortization
Finite-lived intangibles, accumulated amortization, beginning	150,701	127,343
Finite-lived intangibles, accumulated amortization, additions	21,767	23,349
Finite-lived intangible assets, accumulated amortization, reductions	(16,136)
Finite-lived intangibles, accumulated amortization, effects of foreign currency exchange rates	(68)	9
Finite-lived intangibles, accumulated amortization, ending	156,264	150,701
Gross Carrying Amounts
Reclassifications	25,152
Impairment loss	195,900
Finite-lived intangible assets			234,019
Indefinite- Lived Tradenames
Indefinite- Lived Tradenames
Indefinite-lived intangibles, beginning	2,490,303	2,589,155
Indefinite-lived intangibles, reductions	(30,562)
Indefinite-lived intangibles, tradename impairment	(154,967)	(99,300)
Indefinite-lived intangibles, effects of foreign currency exchange rates	(6,431)	448
Indefinite-lived intangibles, ending	2,273,191	2,490,303
Gross Carrying Amounts
Reclassifications	(25,152)
Indefinite-lived intangible assets	$ 2,490,303	$ 2,589,155	$ 2,273,191	$ 2,490,303

Intangible Assets (Narrative) (Details) $ in Thousands		1 Months Ended	11 Months Ended	12 Months Ended
Intangible Assets (Narrative) (Details) $ in Thousands	Jul. 02, 2018 USD ($)	Aug. 31, 2016 USD ($)	Feb. 28, 2018 trade_name	Mar. 31, 2019 USD ($)	Mar. 31, 2018 USD ($)
Schedule of Intangible Assets [Line Items]
Number of indefinite-lived trade names exceeding carrying value by less than 10% \| trade_name			2
Impairment of indefinite-lived assets				$ 155,000
Intangible assets, useful lives				15 years
Intangible assets, tradename impairment					$ 600
Finite-lived intangible assets, weighted average remaining period				11 years 10 months 24 days
Amortization of intangible assets				$ 21,767	23,349
Minimum
Schedule of Intangible Assets [Line Items]
Intangible assets, useful lives				10 years
Maximum
Schedule of Intangible Assets [Line Items]
Intangible assets, useful lives				30 years
Finite-Lived Tradenames and Customer Relationships
Schedule of Intangible Assets [Line Items]
Intangible assets, tradename impairment				$ 40,953	624
Amortization of intangible assets				21,767	23,349
Indefinite- Lived Tradenames
Schedule of Intangible Assets [Line Items]
Indefinite-lived intangibles, reductions				(30,562)
Impairment of indefinite-lived assets				154,967	99,300
Comet Brand
Schedule of Intangible Assets [Line Items]
Indefinite-lived intangibles, reductions		$ (9,000)
Impairment of indefinite-lived assets					70,700
Beano Brand
Schedule of Intangible Assets [Line Items]
Impairment of indefinite-lived assets					$ 28,600
Disposal group, disposed of by sale, not discontinued operations \| Household Cleaning \| Household Cleaning \| Finite-Lived Tradenames and Customer Relationships
Schedule of Intangible Assets [Line Items]
Finite-lived intangible assets, written off	$ 18,800
Disposal group, disposed of by sale, not discontinued operations \| Household Cleaning \| Household Cleaning \| Indefinite- Lived Tradenames
Schedule of Intangible Assets [Line Items]
Indefinite-lived intangibles, reductions	$ (30,500)
Measurement Input, Cap Rate
Schedule of Intangible Assets [Line Items]
Indefinite-lived intangible asset, increase (decrease) in measurement input					0.50%
Measurement Input, Long-term Revenue Growth Rate \| Tradenames
Schedule of Intangible Assets [Line Items]
Indefinite-lived intangible asset, increase (decrease) in measurement input					(0.50%)
increase In Measurement Input
Schedule of Intangible Assets [Line Items]
Sensitivity analysis of fair value, impact of change in measurement input				17,400
Decrease In Measurement Input
Schedule of Intangible Assets [Line Items]
Sensitivity analysis of fair value, impact of change in measurement input				$ 8,900

Intangible Assets (Expected Amortization Expense) (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Mar. 31, 2018
Intangible Assets, Net (Excluding Goodwill) [Abstract]
2020	$ 19,642
2021	19,646
2022	19,644
2023	19,644
2024	19,614
Thereafter	135,829
Intangible assets, net	$ 234,019	$ 290,613

Other Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Mar. 31, 2018
Payables and Accruals [Abstract]
Accrued marketing costs	$ 31,228	$ 21,473
Accrued compensation costs	10,958	10,591
Accrued broker commissions	1,361	1,487
Income taxes payable	88	1,901
Accrued professional fees	2,441	2,244
Accrued production costs	6,788	7,392
Other accrued liabilities	7,799	7,013
Total other accrued liabilities	$ 60,663	$ 52,101

Long-Term Debt (Narrative 2012 Term Loan and 2012 ABL Revolver) (Details) - USD ($)							12 Months Ended
	Mar. 21, 2018	Feb. 04, 2016	Jun. 09, 2015	Sep. 03, 2014	Feb. 21, 2013	Jan. 31, 2012	Mar. 31, 2019	Jan. 26, 2017	May 08, 2015
2012 ABL Revolver \| Revolving Credit Facility
Debt Instrument [Line Items]
Debt instrument, term						5 years
Line of credit facility, maximum borrowing capacity						$ 50,000,000.0	$ 135,000,000
Revolving credit facility, increase in borrowing capacity							$ 85,000,000
Debt instrument, interest rate, decrease (as percent)							0.25%
Line of credit facility, commitment fee (as percent)						0.50%
Line of credit facility, conditional commitment fee (as percent)							0.375%
Revolver increase in accordion feature			$ 35,000,000.0
Debt instrument, average interest rate (as percent)							3.80%
2012 ABL Revolver \| Revolving Credit Facility \| LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate, fixed component (as percent)				1.00%
2012 ABL Revolver \| Revolving Credit Facility \| LIBOR \| Minimum
Debt Instrument [Line Items]
Debt instrument, conditional variable rate (as percent)				2.00%
2012 ABL Revolver \| Revolving Credit Facility \| LIBOR \| Maximum
Debt Instrument [Line Items]
Debt instrument, conditional variable rate (as percent)				2.25%
2012 ABL Revolver \| Revolving Credit Facility \| Base Rate \| Minimum
Debt Instrument [Line Items]
Debt instrument, conditional variable rate (as percent)				1.00%
2012 ABL Revolver \| Revolving Credit Facility \| Base Rate \| Maximum
Debt Instrument [Line Items]
Debt instrument, conditional variable rate (as percent)				1.25%
2012 ABL Revolver \| Revolving Credit Facility \| Federal Funds Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate, fixed component (as percent)				0.50%
ABL Revolver Amendment 4 \| Revolving Credit Facility
Debt Instrument [Line Items]
Debt instrument, term			5 years
2012 ABL Revolver, Amendment No. 3 \| Revolving Credit Facility
Debt Instrument [Line Items]
Revolving credit facility, increase in borrowing capacity				$ 40,000,000.0
ABL Amendment No. 5 \| Revolving Credit Facility
Debt Instrument [Line Items]
Debt Instrument, temporary suspension of financial reporting covenant, period		60 days
2012 ABL Revolver, Amendment No. 6 \| Revolving Credit Facility
Debt Instrument [Line Items]
Revolving credit facility, increase in borrowing capacity								$ 40,000,000.0
Term Loans \| 2012 Term Loan
Debt Instrument [Line Items]
Debt instrument, face amount						$ 660,000,000.0
Debt instrument, term						7 years
Debt instrument, discount (as percent)						1.50%
Proceeds from issuance of long-term debt						$ 650,100,000
Term Loans \| 2012 Term Loan, Amendment No. 1 \| LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (as percent)					2.75%
Debt instrument, reference rate floor (as percent)					1.00%
Term Loans \| 2012 Term Loan, Amendment No. 1 \| Base Rate
Debt Instrument [Line Items]
Debt instrument, reference rate floor (as percent)					2.00%
Term Loans \| 2012 Term Loan, Amendment No. 2
Debt Instrument [Line Items]
Debt instrument, reference rate floor (as percent)				1.00%
Term Loans \| 2012 Term Loan, Amendment No. 2 \| LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (as percent)				3.125%
Term Loans \| 2012 Term Loan, Amendment No. 2 \| Base Rate
Debt Instrument [Line Items]
Debt instrument, reference rate floor (as percent)				2.00%
Term Loans \| 2012 Senior Notes \| LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (as percent)							2.00%
Term Loans \| 2012 Senior Notes \| Base Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (as percent)							1.00%
Term Loans \| Term B-5 Loans \| LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (as percent)	2.00%
Debt instrument, reference rate floor (as percent)	0.00%
Term Loans \| Term B-5 Loans \| Base Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (as percent)	1.00%
Debt instrument, reference rate floor (as percent)	1.00%
2012 Term B-3 Loan \| 2012 Term Loan, Amendment No. 3
Debt Instrument [Line Items]
Debt instrument, face amount									$ 852,500,000.0
2012 Term B-1 Loan \| 2012 Term Loan, Amendment No. 3
Debt Instrument [Line Items]
Debt instrument, face amount									207,500,000.0
2012 Term B-2 Loan \| 2012 Term Loan, Amendment No. 2
Debt Instrument [Line Items]
Debt instrument, face amount				$ 720,000,000.0
2012 Term B-2 Loan \| 2012 Term Loan, Amendment No. 2 \| LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (as percent)				3.50%
Debt instrument, reference rate floor (as percent)				1.00%
2012 Term B-2 Loan \| 2012 Term Loan, Amendment No. 2 \| Base Rate
Debt Instrument [Line Items]
Debt instrument, reference rate floor (as percent)				2.00%
Interest rate, contingent margin step-down per annum (as percent)				3.25%
2012 Term B-2 Loan \| 2012 Term Loan, Amendment No. 3
Debt Instrument [Line Items]
Debt instrument, face amount									$ 645,000,000.0
2012 Term B-4 Loans \| 2012 Senior Notes
Debt Instrument [Line Items]
Debt instrument, face amount								$ 1,427,000,000.0
Debt instrument, average interest rate (as percent)							4.90%

Long-Term Debt (Narrative 2013 Senior Notes) (Details) - Senior Notes - 2013 Senior Notes - USD ($)	Mar. 31, 2019	Dec. 17, 2013
Debt Instrument [Line Items]
Debt instrument, face amount		$ 400,000,000.0
Debt instrument, stated interest rate (as percent)	5.375%	5.375%

Long-Term Debt (Narrative 2016 Senior Notes) (Details) - Senior Notes - 2016 Senior Notes - USD ($)	Mar. 21, 2018	Mar. 31, 2019	Feb. 19, 2016
Debt Instrument [Line Items]
Debt instrument, face amount	$ 250,000,000.0		$ 350,000,000.0
Debt instrument, stated interest rate (as percent)	6.375%	6.375%	6.375%
Issuance price (as percent)	101.00%

Long-Term Debt (Narrative Redemptions and Restrictions) (Details) - USD ($) $ in Thousands		12 Months Ended
	Feb. 19, 2016	Mar. 31, 2019	Mar. 31, 2018
Debt Instrument [Line Items]
Unamortized debt costs		$ 14,402	$ 20,048
Revolving Credit Facility \| 2012 ABL Revolver
Debt Instrument [Line Items]
Unamortized debt costs		800	1,100
Repayments of long-term debt		75,000
Revolving credit facility, remaining borrowing capacity		$ 95,600
Senior Notes \| 2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage of principal amount (as percent)		101.00%
Unamortized debt costs		$ 4,300	3,700
Senior Notes \| 2016 Senior Notes
Debt Instrument [Line Items]
Unamortized debt costs		2,800	5,000
Senior Notes \| Indirect guarantee of indebtedness \| 2016 Senior Notes
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage of principal amount (as percent)	101.00%
Term Loans \| 2012 Term Loan
Debt Instrument [Line Items]
Unamortized debt costs		$ 7,300	$ 11,300

Long-Term Debt (Schedule of Long-term Debt) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 21, 2018	Feb. 19, 2016	Dec. 17, 2013
Debt Instrument [Line Items]
Long-term debt, gross	$ 1,813,000
Long-term debt, gross, excluding current maturities	1,813,000	$ 2,013,000
Less unamortized debt costs	(14,402)	(20,048)
Long-term debt, net	1,798,598	1,992,952
2016 Senior Notes \| Senior Notes
Debt Instrument [Line Items]
Long-term debt, gross	600,000	600,000
Less unamortized debt costs	$ (2,800)	(5,000)
Debt instrument, stated interest rate (as percent)	6.375%		6.375%	6.375%
2013 Senior Notes \| Senior Notes
Debt Instrument [Line Items]
Long-term debt, gross	$ 400,000	400,000
Less unamortized debt costs	$ (4,300)	(3,700)
Debt instrument, stated interest rate (as percent)	5.375%				5.375%
2012 Senior Notes \| Term Loans
Debt Instrument [Line Items]
Long-term debt, gross	$ 738,000	938,000
2012 Senior Notes \| Term Loans \| LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (as percent)	2.00%
Debt instrument, variable rate, minimum	0.00%
2012 Senior Notes \| Term Loans \| Base Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (as percent)	1.00%
Debt instrument, variable rate, minimum	1.00%
2012 ABL Revolver \| Revolving Credit Facility
Debt Instrument [Line Items]
Long-term debt, gross	$ 75,000	75,000
Less unamortized debt costs	$ (800)	$ (1,100)

Long-Term Debt (Maturities of Long-term Debt) (Details) $ in Thousands	Mar. 31, 2019 USD ($)
Debt Disclosure [Abstract]
2020	$ 0
2021	0
2022	475,000
2023	0
2024	1,338,000
Thereafter	0
Long-term debt, gross	$ 1,813,000

Fair Value Measurements (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Mar. 31, 2018
Carrying value \| Senior Notes \| 2016 Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt, fair value	$ 600,000	$ 600,000
Carrying value \| Senior Notes \| 2013 Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt, fair value	400,000	400,000
Carrying value \| Term Loans \| 2012 Term B-5 Loans
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt, fair value	738,000	938,000
Carrying value \| Revolving Credit Facility \| 2012 ABL Revolver
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt, fair value	75,000	75,000
Fair value \| Fair Value, Inputs, Level 2 \| Senior Notes \| 2016 Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt, fair value	606,000	610,500
Fair value \| Fair Value, Inputs, Level 2 \| Senior Notes \| 2013 Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt, fair value	401,500	402,000
Fair value \| Fair Value, Inputs, Level 2 \| Term Loans \| 2012 Term B-5 Loans
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt, fair value	728,775	939,173
Fair value \| Fair Value, Inputs, Level 2 \| Revolving Credit Facility \| 2012 ABL Revolver
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt, fair value	$ 75,000	$ 75,000

Stockholders' Equity (Details)	12 Months Ended
Stockholders' Equity (Details)	Mar. 31, 2019 USD ($) vote / shares $ / shares shares	Mar. 31, 2018 $ / shares shares
Class of Stock [Line Items]
Common stock, shares authorized (in shares) \| shares	250,000,000	250,000,000
Common stock, par value (in USD per share) \| $ / shares	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares) \| shares	5,000,000	5,000,000
Preferred stock, par value (in USD per share) \| $ / shares	$ 0.01	$ 0.01
Voting rights, number of votes per common share owned \| vote / shares	1
Dividends declared on common stock \| $	$ 0
Restricted stock repurchased during period (in shares) \| shares	1,449,750
Restricted stock acquired, average cost per share (in USD per share) \| $ / shares	$ 34.47
Treasury share repurchases \| $	$ 50,000,000
Restricted Shares
Class of Stock [Line Items]
Restricted stock repurchased during period (in shares) \| shares	68,939	20,549
Restricted stock acquired, average cost per share (in USD per share) \| $ / shares	$ 33.09	$ 52.33

Share-Based Compensation (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands				1 Months Ended	12 Months Ended
	May 07, 2018	Aug. 01, 2017	May 31, 2014	Jun. 30, 2014	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase to plan term				10 years
Stock-based compensation costs					$ 7,438	$ 8,909	$ 8,148
Tax benefit recognized from share-based compensation expense					1,400	1,800	2,600
Share-based compensation expense, not yet recognized					$ 5,500
Share-based compensation expense, not yet recognized, period for recognition					10 months 24 days
Total fair value of shares vested					$ 12,000	6,800	6,000
Proceeds from exercise of stock options					2,931	1,620	4,028
Income tax benefit realized from exercise of stock awards					$ 1,300	$ 1,100	$ 2,000
Number of shares available for issuance under plan (in shares)					1,800,000
Options granted (in shares)					294,500	182,800	264,300
Options exercised, intrinsic value					$ 800	$ 1,200	$ 3,200
Performance Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock units granted in period (in shares)	103,406
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock units granted in period (in shares)	100,399	3,779			226,400	105,800	68,400
Options granted (in shares)		1
Award vesting period					3 years
Period following director's term In which stock awards may be settled					6 months
Granted, weighted-average grant-date fair value (in USD per share)					$ 30.09	$ 55.61	$ 55.44
Restricted Stock Units (RSUs) \| Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period					3 years
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted (in shares)	294,484	1
Award grant exercise price (in dollars per share)	$ 29.46
Period following director's term In which stock awards may be settled					6 months
Award exercisability period, from date of grant (not greater than)					10 years
Granted, weighted-average grant-date fair value (in USD per share)					$ 10.22	$ 21.20	$ 21.75
Stock Options \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period					3 years
Stock Options \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period					5 years
2005 Long-term Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for grant (in shares)					5,000,000.0
Number of additional shares authorized under plan (in shares)				1,800,000.0
Maximum number of shares awarded, per employee, annual (in shares)			1,000,000	2,500,000.0

Share-Based Compensation (Restricted Shares Activity) (Details) - Restricted Stock Units (RSUs) - $ / shares			12 Months Ended
	May 07, 2018	Aug. 01, 2017	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Shares
Outstanding, beginning of period (in shares)			393,500	350,100	467,800
Granted (in shares)	100,399	3,779	226,400	105,800	68,400
Vested and issued (in shares)			(175,800)	(53,300)	(94,700)
Forfeited (in shares)			(31,100)	(9,100)	(91,400)
Outstanding, end of period (in shares)			413,000	393,500	350,100
Vested, end of period (in shares)			113,200	90,500	63,400
Weighted-Average Grant-Date Fair Value
Outstanding, beginning of period, weighted-average grant-date fair value (in USD per share)			$ 44.13	$ 39.29	$ 35.22
Granted, weighted-average grant-date fair value (in USD per share)			30.09	55.61	55.44
Vested and issued, weighted-average grant-date fair value (in USD per share)			43.05	34.30	28.51
Forfeited, weighted-average grant-date fair value (in USD per share)			48.32	48.76	41.71
Outstanding, end of period, weighted-average grant-date fair value (in USD per share)			36.58	44.13	39.29
Vested, end of period, weighted-average grant-date fair value (in USD per share)			$ 31.05	$ 29.88	$ 20.12

Share-Based Compensation (Stock Option Valuation Assumptions) (Details) - Stock Options - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	29.60%	35.20%	37.80%
Expected dividends	$ 0	$ 0	$ 0
Expected term in years	6 years	6 years	6 years
Risk-free rate	2.90%	2.20%	1.70%

Share-Based Compensation (Stock Option Activity) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Shares
Outstanding, beginning of period (in shares)	873,200	772,300	727,700
Granted (in shares)	294,500	182,800	264,300
Exercised (in shares)	(97,700)	(55,700)	(126,800)
Forfeited or expired (in shares)	(125,400)	(26,200)	(92,900)
Outstanding, end of period (in shares)	944,600	873,200	772,300
Exercisable, end of period (in shares)	499,400
Weighted-Average Exercise Price
Outstanding, beginning of period, weighted-average exercise price (in USD per share)	$ 41.79	$ 37.70	$ 30.70
Options, grant date fair value (in USD per share)	29.46	56.11	55.86
Exercised, weighted-average exercise price (in USD per share)	30.02	29.08	31.75
Forfeited or expired, weighted-average exercise price (in USD per share)	47.16	48.19	42.66
Outstanding, end of period, weighted-average exercise price (in USD per share)	38.45	$ 41.79	$ 37.70
Exercisable, end of period, weighted-average exercise price (in USD per share)	$ 37.87
Options
Outstanding, end of period, weighted-average remaining contractual term	7 years
Exercisable, end of period, weighted-average remaining contractual term	5 years 6 months
Outstanding, end of period, aggregate intrinsic value	$ 2,048
Exercisable, end of period, aggregate intrinsic value	$ 1,921

Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Accumulated Other Comprehensive Income (Loss) [Line Items]
Components of Accumulated Other Comprehensive Loss	$ 1,095,831	$ 1,178,610	$ 822,549	$ 744,336
Reclassification from AOCI	0	0
Accumulated other comprehensive loss, net of tax
Accumulated Other Comprehensive Income (Loss) [Line Items]
Components of Accumulated Other Comprehensive Loss	(25,747)	(19,315)	$ (26,352)	$ (23,525)
Cumulative translation adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Components of Accumulated Other Comprehensive Loss	(26,878)	(20,398)
Unrecognized net gain on pension plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Components of Accumulated Other Comprehensive Loss	$ 1,131	$ 1,083

Employee Retirement Plans (Narrative) (Details) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined contribution plan, minimum annual contributions per participating employee (as percent)	1.00%
Defined contribution plan, maximum annual contributions per employee (as percent)	70.00%
Defined contribution plan, cost recognized	$ 1,500,000	$ 1,600,000	$ 900,000
Defined benefit obligation	60,334,000	61,882,000	61,714,000
Net periodic benefit cost (income) (less than $1.0 million)	$ (690,000)	$ (372,000)	(6,000)
Expected return on plan assets, net of administrative fees (as percent)	5.75%	6.25%
Qualified plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Contributions to the qualified plan	$ 1,000,000	$ 0	$ 6,000,000
Unfunded plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined benefit obligation	$ 4,600,000	$ 5,900,000
Contribution Tranche One
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined contribution plan, employer matching contribution, percent of match (as percent)	100.00%
Defined contribution plan, employer matching contribution, percent of employees pay (as percent)	3.00%
Contribution Tranche Two
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined contribution plan, employer matching contribution, percent of match (as percent)	50.00%
Defined contribution plan, employer matching contribution, percent of employees pay (as percent)	3.00%

Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2017	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Net gain related to deferred tax liability	$ 267,000
Net gain related to the lower blended tax rate	3,200
Net gain	270,200
Repatriation charge	1,900
Long-term deferred tax assets	1,000	$ 1,000
Valuation allowance	609	3,236
Unrecognized tax benefits	$ 10,827	$ 9,874	$ 3,651	$ 4,084

Employee Retirement Plans (Periodic Service Costs) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Change in benefit obligation:
Projected benefit obligation at beginning of period	$ 61,882	$ 61,714
Interest cost	2,380	2,529	$ 456
Actuarial (gain) loss	(744)	800
Benefits paid	(3,184)	(3,161)
Projected benefit obligations at end of year	60,334	61,882	61,714
Change in plan assets:
Fair value of plan assets at beginning of period	50,508	47,772
Actual return on plan assets	2,416	5,505
Employer contribution	1,375	392
Benefits paid	(3,184)	(3,161)
Fair value of plan assets at end of year	51,115	50,508	$ 47,772
Funded status at end of year	$ (9,219)	$ (11,374)

Income Taxes (Income Before Continuing Operations) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Income from Continuing Operations before Income Taxes:
United States									$ (52,313)	$ 84,435	$ 93,582
Foreign									14,258	22,651	17,268
(Loss) income before income taxes	$ (179,030)	$ 50,996	$ 43,519	$ 46,460	$ (52,562)	$ 57,639	$ 49,321	$ 52,688	$ (38,055)	$ 107,086	$ 110,850

Employee Retirement Plans (Amounts Recognized in the Balance Sheet) (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Current liability	$ 361	$ 461
Long-term liability	8,858	10,913
Total	$ 9,219	$ 11,374

Income Taxes (Components of Provision for Income Taxes) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Current
Federal									$ 27,629	$ 31,327	$ 40,183
State									3,156	2,686	2,808
Foreign									7,193	5,588	4,242
Deferred
Federal									(35,760)	(270,796)	(5,421)
State									(4,101)	(1,240)	(163)
Foreign									(372)	(49)	(194)
Total (benefit) provision for income taxes	$ (39,756)	$ 12,829	$ 12,678	$ 11,994	$ (12,875)	$ (257,154)	$ 18,616	$ 18,929	$ (2,255)	$ (232,484)	$ 41,455

Employee Retirement Plans (Expected Return on Plan Assets) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Interest cost	$ 2,380	$ 2,529	$ 456
Expected return on assets	(3,070)	(2,901)	(462)
Net periodic benefit cost (income)	$ (690)	$ (372)	$ (6)

Income Taxes (Components of Deferred Tax Balances) (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Mar. 31, 2018
Deferred Tax Assets
Allowance for doubtful accounts and sales returns	$ 3,285	$ 2,806
Inventory capitalization	1,245	1,176
Inventory reserves	1,267	540
Net operating loss carryforwards	226	609
State income taxes	9,003	10,154
Accrued liabilities	1,785	2,210
Accrued compensation	4,416	4,992
Stock compensation	4,206	5,038
Foreign tax credit	3,236	0
Interest	154	0
Other	7,691	4,975
Total deferred tax assets	36,514	32,500
Deferred Tax Liabilities
Property, plant and equipment	(6,002)	(6,032)
Intangible assets	(425,134)	(467,388)
Adoption of revenue recognition standard	(721)	0
Total deferred tax liabilities	(431,857)	(473,420)
Net deferred tax liability before valuation allowance	(395,343)	(440,920)
Valuation allowance	(3,236)	(609)
Net deferred tax liability	$ (398,579)	$ (441,529)

Employee Retirement Plans (Expected Benefit Payments) (Details) $ in Thousands	Mar. 31, 2019 USD ($)
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
2020 (expectation) to participant benefits	$ 1,361
2020	3,371
2021	3,472
2022	3,592
2023	3,678
2024	3,743
2025-2029	$ 18,771

Income Taxes (Reconciliation of Effective Tax Rate) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Income tax (benefit) provision at statutory rate	$ (7,992)	$ 37,480	$ 38,798
Income tax provision at statutory rate (as percent)	21.00%	35.00%	35.00%
Foreign tax provision (benefit)	$ 2,866	$ (2,084)	$ (2,322)
Foreign tax benefit provision (as percent)	(7.50%)	(1.90%)	(2.10%)
State income taxes, net of federal income tax benefit	$ (1,710)	$ 1,414	$ 1,820
State income taxes, net of federal income tax benefit (as percent)	4.50%	1.30%	1.70%
Impact of tax legislation	$ 0	$ (268,244)	$ 0
Impact of tax (as percent)	0.00%	(250.50%)	0.00%
Goodwill impairment	$ 5,616	$ 0	$ 3,208
Goodwill impairment (as percent)	(14.80%)	0.00%	2.90%
R&D	$ (629)	$ 0	$ 0
R&D (as percent)	1.70%	(0.00%)	(0.00%)
Compensation limitations	$ 296	$ 0	$ 0
Compensation limitations (as percent)	(0.80%)	0.00%	0.00%
Valuation allowance	$ 2,627	$ (2,828)	$ 0
Valuation allowance (as percent)	(6.90%)	(2.60%)	0.00%
Gain on sale	$ 1,312	$ 0	$ 0
Gain on sale (as percent)	(3.40%)	0.00%	0.00%
Nondeductible transaction costs	$ 0	$ 0	$ 686
Nondeductible transaction costs (as percent)	0.00%	0.00%	0.60%
Nondeductible compensation	$ 0	$ 0	$ 342
Nondeductible compensation (as percent)	0.00%	0.00%	0.30%
Other	$ (4,641)	$ 1,778	$ (1,077)
Other (as percent)	12.10%	1.60%	(1.00%)
Total (benefit) provision for income taxes	$ (2,255)	$ (232,484)	$ 41,455
Total provision for income taxes (as percent)	5.90%	(217.10%)	37.40%

Employee Retirement Plans (Category of Plan Assets) (Details)	Mar. 31, 2019	Mar. 31, 2018
Defined Benefit Plan Disclosure [Line Items]
Target Allocation	100.00%
Percentage of Plan Assets	100.00%	100.00%
Domestic large cap equities
Defined Benefit Plan Disclosure [Line Items]
Target Allocation	18.00%
Percentage of Plan Assets	18.00%	21.00%
Domestic small/mid cap equities
Defined Benefit Plan Disclosure [Line Items]
Target Allocation	5.00%
Percentage of Plan Assets	5.00%	6.00%
International equities
Defined Benefit Plan Disclosure [Line Items]
Target Allocation	15.00%
Percentage of Plan Assets	15.00%	18.00%
Fixed income and cash
Defined Benefit Plan Disclosure [Line Items]
Target Allocation	62.00%
Percentage of Plan Assets	62.00%	55.00%

Income Taxes (Uncertain Tax Liability Activity) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance – beginning of year	$ 10,827	$ 3,651	$ 4,084
Additions based on tax positions related to the current year	585	7,286	583
Reductions based on lapse of statute of limitations	(650)	(110)	(1,016)
Payments and other movements	(888)	0	0
Balance – end of year	$ 9,874	$ 10,827	$ 3,651

Employee Retirement Plans (Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Unrecognized actuarial (gain)	$ (1,469)	$ (1,407)	$ 399
Unrecognized prior service credit	0	$ 0	$ 0
Amounts expected to be reclassified from accumulated other comprehensive income (loss) during 2020:
Unrecognized actuarial (loss)	0
Unrecognized prior service credit	$ 0

Employee Retirement Plans (Weighted Average Assumptions) (Details)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Defined Benefit Plan Disclosure [Line Items]
Expected return on plan assets, net of administrative fees	5.75%	6.25%
Rate of compensation increase	0.00%	0.00%
Minimum
Defined Benefit Plan Disclosure [Line Items]
Discount rate	3.80%	3.93%
Maximum
Defined Benefit Plan Disclosure [Line Items]
Discount rate	3.99%	4.07%

Commitments and Contingencies (Future Minimum Rental Payments) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Operating Leased Assets [Line Items]
2020	$ 3,142
2021	2,881
2022	2,478
2023	1,789
2024	1,705
Thereafter	6,780
Total future minimum payments due	18,775	$ 20,987
Less: Sublease rentals	(509)	(1,018)
Minimum lease payments, net of sublease rentals	18,266	19,969
Operating leases, rent expense	2,400	$ 1,900	$ 2,000
Facilities
Operating Leased Assets [Line Items]
2020	2,828
2021	2,633
2022	2,265
2023	1,684
2024	1,705
Thereafter	6,780
Total future minimum payments due	17,895
Equipment
Operating Leased Assets [Line Items]
2020	314
2021	248
2022	213
2023	105
2024	0
Thereafter	0
Total future minimum payments due	$ 880

Commitments and Contingencies (Long-term Supply Agreement) (Details) - Third-party Manufacturing $ in Thousands	Mar. 31, 2019 USD ($)
Long-term Purchase Commitment [Line Items]
2020	$ 9,802
2021	9,719
2022	9,497
2023	1,650
2024	0
Thereafter	0
Total purchase commitment	$ 30,668

Concentrations of Risk (Details) - manufacturer	12 Months Ended
Concentrations of Risk (Details) - manufacturer	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Concentration Risk [Line Items]
Number of third-party manufacturers	113
Sales \| Product concentration risk \| Top 5 brands
Concentration Risk [Line Items]
Concentration risk, percentage	42.90%	41.20%	40.00%
Sales \| Customer concentration risk \| Walmart
Concentration Risk [Line Items]
Concentration risk, percentage	23.70%	23.80%	21.10%
Sales \| Supplier concentration risk
Concentration Risk [Line Items]
Concentration risk, percentage	65.60%	73.60%
Number of third-party manufacturers with long-term contracts	33	46
Accounts receivable \| Customer concentration risk \| Walmart
Concentration Risk [Line Items]
Concentration risk, percentage	25.10%

Business Segments (Information on Operating and Reportable Segments) (Details) - USD ($)	3 Months Ended								12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Segment Reporting Information, Profit (Loss):
Total segment revenues	$ 241,026,000	$ 241,414,000	$ 239,357,000	$ 253,980,000	$ 255,965,000	$ 270,615,000	$ 258,026,000	$ 256,573,000	$ 975,777,000	$ 1,041,179,000	$ 882,060,000
Goodwill and tradename impairment	229,461,000	0	0	0	99,924,000	0	0	0	229,461,000	99,924,000	0
Goodwill, impairment loss									33,541,000	0
Goodwill and tradename impairment									195,920,000	99,924,000
Cost of sales	102,780,000	102,179,000	101,885,000	113,357,000	114,708,000	122,941,000	113,928,000	113,097,000	420,201,000	464,674,000	381,774,000
Gross profit	138,246,000	139,235,000	137,472,000	140,623,000	141,257,000	147,674,000	144,098,000	143,476,000	555,576,000	576,505,000	500,286,000
Advertising and promotion	34,433,000	34,504,000	37,042,000	37,111,000	35,319,000	35,835,000	39,188,000	36,944,000	143,090,000	147,286,000	128,359,000
Contribution margin									412,486,000	429,219,000	371,927,000
Other operating expenses									344,983,000	213,745,000	166,284,000
Operating income	(153,449,000)	77,541,000	70,924,000	72,487,000	(23,096,000)	83,890,000	75,725,000	78,955,000	67,503,000	215,474,000	205,643,000
Other expense									105,558,000	108,388,000	94,793,000
Loss before income taxes	(179,030,000)	50,996,000	43,519,000	46,460,000	(52,562,000)	57,639,000	49,321,000	52,688,000	(38,055,000)	107,086,000	110,850,000
(Benefit) provision for income taxes	(39,756,000)	12,829,000	12,678,000	11,994,000	(12,875,000)	(257,154,000)	18,616,000	18,929,000	(2,255,000)	(232,484,000)	41,455,000
Net (loss) income	(139,274,000)	38,167,000	30,841,000	34,466,000	$ (39,687,000)	$ 314,793,000	$ 30,705,000	$ 33,759,000	(35,800,000)	339,570,000	69,395,000
Loss on divestitures and sales of property and equipment	$ 0	$ 0	$ (1,284,000)	$ 0					(1,284,000)	0	51,820,000
Intangible assets, tradename impairment										600,000
Disposal held for sale \| Pediacare, New Skin, Fiber Choice, EPT, Dermoplast, and Comet
Segment Reporting Information, Profit (Loss):
Loss on divestitures and sales of property and equipment										51,800,000
North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total segment revenues									862,446,000	868,874,000	720,824,000
Goodwill, impairment loss									33,541,000
Cost of sales									364,533,000	357,298,000	282,750,000
Gross profit									497,913,000	511,576,000	438,074,000
Advertising and promotion									126,374,000	129,058,000	112,465,000
Contribution margin									371,539,000	382,518,000	325,609,000
North American OTC Healthcare \| Intersegment Eliminations
Segment Reporting Information, Profit (Loss):
Total segment revenues									(7,400,000)	(7,700,000)	(4,200,000)
International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total segment revenues									93,520,000	91,658,000	73,304,000
Goodwill, impairment loss									0
Cost of sales									39,080,000	40,244,000	30,789,000
Gross profit									54,440,000	51,414,000	42,515,000
Advertising and promotion									16,286,000	16,267,000	13,434,000
Contribution margin									38,154,000	35,147,000	29,081,000
Household Cleaning
Segment Reporting Information, Profit (Loss):
Total segment revenues									19,811,000	80,647,000	87,932,000
Goodwill, impairment loss									0
Cost of sales									16,588,000	67,132,000	68,235,000
Gross profit									3,223,000	13,515,000	19,697,000
Advertising and promotion									430,000	1,961,000	2,460,000
Contribution margin									2,793,000	11,554,000	$ 17,237,000
Finite-Lived Tradenames and Customer Relationships
Segment Reporting Information, Profit (Loss):
Goodwill and tradename impairment									195,900,000
Intangible assets, tradename impairment									$ 40,953,000	$ 624,000

Business Segments (Revenue by Product) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Revenue from External Customer [Line Items]
Total segment revenues	$ 241,026	$ 241,414	$ 239,357	$ 253,980	$ 255,965	$ 270,615	$ 258,026	$ 256,573	$ 975,777	$ 1,041,179	$ 882,060
Analgesics
Revenue from External Customer [Line Items]
Total segment revenues									114,178	119,417	122,175
Cough & Cold
Revenue from External Customer [Line Items]
Total segment revenues									103,123	111,847	108,785
Women's Health
Revenue from External Customer [Line Items]
Total segment revenues									258,479	259,384	150,882
Gastrointestinal
Revenue from External Customer [Line Items]
Total segment revenues									160,462	152,236	101,312
Eye & Ear Care
Revenue from External Customer [Line Items]
Total segment revenues									112,837	104,052	109,693
Dermatologicals
Revenue from External Customer [Line Items]
Total segment revenues									97,972	96,888	87,353
Oral Care
Revenue from External Customer [Line Items]
Total segment revenues									103,432	111,002	108,099
Other OTC
Revenue from External Customer [Line Items]
Total segment revenues									5,483	5,706	5,829
Household Cleaning
Revenue from External Customer [Line Items]
Total segment revenues									19,811	80,647	87,932
North American OTC Healthcare
Revenue from External Customer [Line Items]
Total segment revenues									862,446	868,874	720,824
North American OTC Healthcare \| Analgesics
Revenue from External Customer [Line Items]
Total segment revenues									113,563	118,610	120,253
North American OTC Healthcare \| Cough & Cold
Revenue from External Customer [Line Items]
Total segment revenues									83,168	93,537	90,795
North American OTC Healthcare \| Women's Health
Revenue from External Customer [Line Items]
Total segment revenues									244,927	247,244	147,071
North American OTC Healthcare \| Gastrointestinal
Revenue from External Customer [Line Items]
Total segment revenues									125,416	117,627	76,500
North American OTC Healthcare \| Eye & Ear Care
Revenue from External Customer [Line Items]
Total segment revenues									101,128	92,308	97,618
North American OTC Healthcare \| Dermatologicals
Revenue from External Customer [Line Items]
Total segment revenues									95,801	94,775	85,194
North American OTC Healthcare \| Oral Care
Revenue from External Customer [Line Items]
Total segment revenues									92,964	99,072	97,586
North American OTC Healthcare \| Other OTC
Revenue from External Customer [Line Items]
Total segment revenues									5,479	5,701	5,807
International OTC Healthcare
Revenue from External Customer [Line Items]
Total segment revenues									93,520	91,658	73,304
International OTC Healthcare \| Analgesics
Revenue from External Customer [Line Items]
Total segment revenues									615	807	1,922
International OTC Healthcare \| Cough & Cold
Revenue from External Customer [Line Items]
Total segment revenues									19,955	18,310	17,990
International OTC Healthcare \| Women's Health
Revenue from External Customer [Line Items]
Total segment revenues									13,552	12,140	3,811
International OTC Healthcare \| Gastrointestinal
Revenue from External Customer [Line Items]
Total segment revenues									35,046	34,609	24,812
International OTC Healthcare \| Eye & Ear Care
Revenue from External Customer [Line Items]
Total segment revenues									11,709	11,744	12,075
International OTC Healthcare \| Dermatologicals
Revenue from External Customer [Line Items]
Total segment revenues									2,171	2,113	2,159
International OTC Healthcare \| Oral Care
Revenue from External Customer [Line Items]
Total segment revenues									10,468	11,930	10,513
International OTC Healthcare \| Other OTC
Revenue from External Customer [Line Items]
Total segment revenues									4	5	22
Household Cleaning
Revenue from External Customer [Line Items]
Total segment revenues									19,811	80,647	87,932
Household Cleaning \| Analgesics
Revenue from External Customer [Line Items]
Total segment revenues									0	0	0
Household Cleaning \| Cough & Cold
Revenue from External Customer [Line Items]
Total segment revenues									0	0	0
Household Cleaning \| Women's Health
Revenue from External Customer [Line Items]
Total segment revenues									0	0	0
Household Cleaning \| Gastrointestinal
Revenue from External Customer [Line Items]
Total segment revenues									0	0	0
Household Cleaning \| Eye & Ear Care
Revenue from External Customer [Line Items]
Total segment revenues									0	0	0
Household Cleaning \| Dermatologicals
Revenue from External Customer [Line Items]
Total segment revenues									0	0	0
Household Cleaning \| Oral Care
Revenue from External Customer [Line Items]
Total segment revenues									0	0	0
Household Cleaning \| Other OTC
Revenue from External Customer [Line Items]
Total segment revenues									0	0	0
Household Cleaning \| Household Cleaning
Revenue from External Customer [Line Items]
Total segment revenues									$ 19,811	$ 80,647	$ 87,932

Business Segments (Revenue by Geographic Area) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Revenues from External Customers and Long-Lived Assets [Line Items]
Total segment revenues	$ 241,026	$ 241,414	$ 239,357	$ 253,980	$ 255,965	$ 270,615	$ 258,026	$ 256,573	$ 975,777	$ 1,041,179	$ 882,060
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Total segment revenues									837,049	903,511	769,732
Rest of world
Revenues from External Customers and Long-Lived Assets [Line Items]
Total segment revenues									$ 138,728	$ 137,668	$ 112,328

Business Segments (Assets by Segment) (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	$ 578,583	$ 620,098	$ 615,252
Indefinite-lived intangible assets	2,273,191	2,490,303
Finite-lived intangible assets	234,019	290,613
Intangible assets, net (excluding goodwill)	2,507,210	2,780,916
Intangible assets, net (including goodwill)	3,085,793	3,401,014
North American OTC Healthcare
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	547,393	580,934	576,453
Indefinite-lived intangible assets	2,195,617	2,375,736
Finite-lived intangible assets	228,743	265,356
Intangible assets, net (excluding goodwill)	2,424,360	2,641,092
Intangible assets, net (including goodwill)	2,971,753	3,222,026
International OTC Healthcare
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	31,190	32,919	32,554
Indefinite-lived intangible assets	77,574	84,006
Finite-lived intangible assets	5,276	6,068
Intangible assets, net (excluding goodwill)	82,850	90,074
Intangible assets, net (including goodwill)	114,040	122,993
Household Cleaning
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	0	6,245	6,245
Indefinite-lived intangible assets	0	30,561
Finite-lived intangible assets	0	19,189
Intangible assets, net (excluding goodwill)	0	49,750
Intangible assets, net (including goodwill)	0	55,995
Finite-Lived Tradenames and Customer Relationships
Segment Reporting, Asset Reconciling Item [Line Items]
Finite-lived intangible assets	234,019
Indefinite- Lived Tradenames
Segment Reporting, Asset Reconciling Item [Line Items]
Indefinite-lived intangible assets	$ 2,273,191	$ 2,490,303	$ 2,589,155

Unaudited Quarterly Financial Information (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Total revenues	$ 241,026	$ 241,414	$ 239,357	$ 253,980	$ 255,965	$ 270,615	$ 258,026	$ 256,573	$ 975,777	$ 1,041,179	$ 882,060
Cost of sales	102,780	102,179	101,885	113,357	114,708	122,941	113,928	113,097	420,201	464,674	381,774
Gross profit	138,246	139,235	137,472	140,623	141,257	147,674	144,098	143,476	555,576	576,505	500,286
Operating Expenses
Advertising and promotion	34,433	34,504	37,042	37,111	35,319	35,835	39,188	36,944	143,090	147,286	128,359
General and administrative	21,299	20,485	24,034	23,941	22,164	20,820	21,999	20,410	89,759	85,393	89,113
Depreciation and amortization	6,502	6,705	6,756	7,084	6,946	7,129	7,186	7,167	27,047	28,428	25,351
(Gain) loss on divestitures	0	0	(1,284)	0					(1,284)	0	51,820
Goodwill and tradename impairment	229,461	0	0	0	99,924	0	0	0	229,461	99,924	0
Total operating expenses	291,695	61,694	66,548	68,136	164,353	63,784	68,373	64,521	488,073	361,031	294,643
Operating income	(153,449)	77,541	70,924	72,487	(23,096)	83,890	75,725	78,955	67,503	215,474	205,643
Net interest expense	25,745	26,327	27,070	25,940	26,838	25,864	26,836	26,341
Loss on extinguishment of debt					2,901	0	0	0	0	2,901	1,420
Other expense (income), net	(164)	218	335	87	(273)	387	(432)	(74)	476	(392)	30
(Loss) income before income taxes	(179,030)	50,996	43,519	46,460	(52,562)	57,639	49,321	52,688	(38,055)	107,086	110,850
Provision (benefit) for income taxes	(39,756)	12,829	12,678	11,994	(12,875)	(257,154)	18,616	18,929	(2,255)	(232,484)	41,455
Net (loss) income	$ (139,274)	$ 38,167	$ 30,841	$ 34,466	$ (39,687)	$ 314,793	$ 30,705	$ 33,759	$ (35,800)	$ 339,570	$ 69,395
Earnings (loss) per share:
Basic (in USD per share)	$ (2.68)	$ 0.74	$ 0.59	$ 0.65	$ (0.75)	$ 5.93	$ 0.58	$ 0.64	$ (0.69)	$ 6.40	$ 1.31
Diluted (in USD per share)	$ (2.68)	$ 0.73	$ 0.59	$ 0.65	$ (0.75)	$ 5.88	$ 0.57	$ 0.63	$ (0.69)	$ 6.34	$ 1.30
Weighted average shares outstanding:
Basic (in shares)	51,912	51,881	51,841	52,640	53,131	53,129	53,098	53,038	52,068	53,099	52,976
Diluted (in shares)	51,912	52,202	52,153	52,942	53,131	53,543	53,539	53,509	52,068	53,526	53,362
Comprehensive (loss) income, net of tax:
Currency translation adjustments	$ 659	$ (2,020)	$ (2,145)	$ (2,974)	$ (2,625)	$ 4,492	$ 2,716	$ 1,119	$ (6,480)	$ 5,702	$ (2,575)
Unrecognized net gain (loss) on pension plans	48	0	0	0	1,334	0	0	1	48	1,335	(252)
Total other comprehensive (loss) income	707	(2,020)	(2,145)	(2,974)	(1,291)	4,492	2,716	1,120	(6,432)	7,037	(2,827)
Comprehensive (loss) income	$ (138,567)	$ 36,147	$ 28,696	$ 31,492	$ (40,978)	$ 319,285	$ 33,421	$ 34,879	$ (42,232)	$ 346,607	$ 66,568

Subsequent Events (Details) - USD ($)				12 Months Ended
Subsequent Events (Details) - USD ($)	May 06, 2019	May 07, 2018	Aug. 01, 2017	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017	May 08, 2019
Subsequent Event [Line Items]
Options, grant date fair value (in USD per share)				$ 29.46	$ 56.11	$ 55.86
Options granted (in shares)				294,500	182,800	264,300
Performance Units
Subsequent Event [Line Items]
Common stock units granted in period (in shares)		103,406
Restricted Stock Units (RSUs)
Subsequent Event [Line Items]
Common stock units granted in period (in shares)		100,399	3,779	226,400	105,800	68,400
Options granted (in shares)			1
Award vesting period				3 years
Stock Options
Subsequent Event [Line Items]
Options granted (in shares)		294,484	1
Subsequent Event
Subsequent Event [Line Items]
Stock repurchase program, authorized amount							$ 50,000,000.0
Options, grant date fair value (in USD per share)	$ 30.56
Subsequent Event \| Performance Units
Subsequent Event [Line Items]
Common stock units granted in period (in shares)	98,645
Award vesting period	3 years
Subsequent Event \| Restricted Stock Units (RSUs)
Subsequent Event [Line Items]
Vesting rights (as percent)	33.30%
Common stock units granted in period (in shares)	89,284
Award vesting period	3 years
Subsequent Event \| Stock Options
Subsequent Event [Line Items]
Expiration period	10 years
Vesting rights (as percent)	33.30%
Options granted (in shares)	281,486
Award vesting period	3 years

Schedule II Valuation and Qualifying Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Reserves for sales returns and allowance
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	$ 8,813	$ 9,429	$ 8,823
Amounts Charged to Expense	56,276	62,953	41,173
Deductions	(56,116)	(63,569)	(41,417)
Other	0	0	850
Balance at End of Year	8,973	8,813	9,429
Reserves for trade promotions
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	11,435	15,193	12,641
Amounts Charged to Expense	90,844	78,669	69,475
Deductions	(88,415)	(82,427)	(69,713)
Other	0	0	2,790
Balance at End of Year	15,491	11,435	15,193
Reserves for consumer coupon redemptions
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	2,645	4,614	4,323
Amounts Charged to Expense	5,199	7,283	7,616
Deductions	(6,669)	(9,252)	(7,745)
Other	0	0	420
Balance at End of Year	1,175	2,645	4,614
Allowance for doubtful accounts
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	1,203	1,352	815
Amounts Charged to Expense	203	187	177
Deductions	(147)	(336)	360
Other	0	0	0
Balance at End of Year	1,259	1,203	1,352
Deferred tax valuation allowance
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	609	3,437	0
Amounts Charged to Expense	2,627	0	0
Deductions	0	0	0
Other	0	(2,828)	3,437
Balance at End of Year	3,236	609	$ 3,437
ASC 606 \| Reserves for trade promotions
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	$ 13,062
Balance at End of Year		$ 13,062

Business and Basis of Presentation (Intangible Assets) (Details)	12 Months Ended
	Mar. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives	15 years
Minimum
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives	10 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives	30 years

Goodwill (Narrative) (Details) - USD ($)	12 Months Ended
Goodwill (Narrative) (Details) - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill, impairment loss	$ 33,541,000	$ 0

Business Segments (Goodwill and Intangible Assets by Geographic Area) (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Mar. 31, 2018
Schedule of Goodwill and Intangible Assets by Geographic Areas [Line Items]
Intangible assets, net (including goodwill)	$ 3,085,793	$ 3,401,014
United States
Schedule of Goodwill and Intangible Assets by Geographic Areas [Line Items]
Intangible assets, net (including goodwill)	2,971,753	3,278,021
Rest of world
Schedule of Goodwill and Intangible Assets by Geographic Areas [Line Items]
Intangible assets, net (including goodwill)	$ 114,040	$ 122,993

Label	Element	Value
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 1,343,000
Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 1,343,000